BioLife Solutions (BLFS) 10-K31 Mar 232022 FY Annual reportFinancial data

Company Profile

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2022	Dec. 31, 2021	Mar. 21, 2023	Jun. 30, 2022
Document Information [Line Items]
Entity Central Index Key	0000834365
Entity Registrant Name	BIOLIFE SOLUTIONS INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Document Transition Report	false
Entity File Number	001-36362
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-3076866
Entity Address, Address Line One	3303 Monte Villa Parkway, Suite 310
Entity Address, City or Town	Bothell
Entity Address, State or Province	WA
Entity Address, Postal Zip Code	98021
City Area Code	425
Local Phone Number	402-1400
Title of 12(b) Security	BioLife Solutions, Inc. Common Stock
Trading Symbol	BLFS
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float				$ 472,940,782
Entity Common Stock, Shares Outstanding			43,211,955
Auditor Firm ID	248	243
Auditor Name	GRANT THORNTON LLP	BDO USA, LLP
Auditor Location	Bellevue, Washington	Seattle, Washington

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 19,442	$ 69,860
Restricted cash	31	10
Available-for-sale securities, current portion	43,260	0
Accounts receivable, trade, net of allowance for doubtful accounts of $739 and $275 as of December 31, 2022 and December 31, 2021, respectively	33,936	23,217
Inventories	34,904	28,345
Prepaid expenses and other current assets	6,879	4,656
Total current assets	138,452	126,088
Assets held for rent, net	9,064	9,809
Property and equipment, net	23,638	17,657
Operating lease right-of-use assets, net	15,292	18,705
Financing lease right-of-use assets, net	272	440
Long-term deposits and other assets	281	325
Available-for-sale securities, long term	1,332	0
Equity Investments	5,069	4,372
Total intangible assets, net	32,088	152,149
Goodwill	224,741	224,741
Total assets	450,229	554,286
Current liabilities:
Accounts payable	15,367	14,945
Accrued expenses and other current liabilities	9,782	6,870	[1]
Sales taxes payable	4,151	2,591
Warranty liability	8,312	9,398
Lease liabilities, operating, current portion	2,860	2,758
Lease liabilities, financing, current portion	158	149
Debt, current portion	1,814	862
Contingent consideration, current portion	2,138	5,127
Total current liabilities	44,582	42,700
Contingent consideration, long-term	2,318	4,900
Lease liabilities, operating, long-term	14,962	16,466
Lease liabilities, financing, long-term	126	291
Debt, long-term	23,793	6,353
Deferred tax liabilities	250	5,487
Other long-term liabilities	10	42
Total liabilities	86,041	76,239
Commitments and Contingencies (Note 12)
Shareholders’ equity:
Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 shares issued and outstanding as of December 31, 2022 and December 31, 2021	0	0
Common stock, $0.001 par value; 150,000,000 shares authorized, 42,832,231 and 41,817,503 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively	43	42
Additional paid-in capital	611,739	585,397
Accumulated other comprehensive loss, net of taxes	(679)	(282)
Accumulated deficit	(246,915)	(107,110)	[2]
Total shareholders’ equity	364,188	478,047
Total liabilities and shareholders’ equity	$ 450,229	$ 554,286

[1]In the prior year Consolidated Balance Sheet as of the year ended December 31, 2021, accrued sales taxes in the amount of $272,000 were recorded within the Accrued expenses and other current liabilities line item on the consolidated balance sheets. These were reclassified to Sales tax payable in the current year.[2]The impact of the error on Accumulated deficit in our Consolidated Balance Sheet as of the year ended December 31, 2019 was negative $133,000, adjusting the ending balance to be $100.2 million when previously reported as $100.1 million.

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Accounts receivable, allowance for doubtful accounts	$ 739	$ 275
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	150,000,000	150,000,000
Common stock, issued (in shares)	42,832,231	41,817,503
Common stock, outstanding (in shares)	42,832,231	41,817,503
Series A Preferred Stock [Member]
Preferred stock, shares designated (in shares)	4,250	4,250
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020
Revenue	$ 161,759	$ 119,156	[1]	$ 48,087	[2]
Costs and operating expenses:
Research and development	14,798	11,821		6,720
Sales and marketing	21,570	14,006		6,413
General and administrative	47,670	33,668		15,273
Impairment of intangible assets	110,364	0		0
Intangible asset amortization	9,697	8,202		3,033
Acquisition costs	18	1,636		668
Change in fair value of contingent consideration	(4,754)	2,875		1,575
Total operating expenses	307,300	154,316		54,328
Operating loss	(145,541)	(35,160)		(6,241)
Other income (expense):
Change in fair value of warrant liability	0	(121)		3,601
Change in fair value of investments	697	0		1,319
Interest (expense) income, net	(687)	(485)		40
Other income	704	289		0
Gain on acquisition of Sexton Biotechnologies, Inc.	0	6,451		0
Total other income, net	714	6,134		4,960
Loss before income tax benefit	(144,827)	(29,026)		(1,281)
Income tax benefit	5,022	20,118		3,264
Net (loss) income	(139,805)	(8,908)	[3]	1,983	[3]
Net (loss) income attributable to common shareholders:
Basic	(139,805)	(8,908)		1,822
Diluted	$ (139,805)	$ (8,908)		$ (1,632)
Basic (in dollars per share)	$ (3.29)	$ (0.23)		$ 0.07
Diluted (in dollars per share)	$ (3.29)	$ (0.23)		$ (0.06)
Weighted average shares used to compute (loss) earnings per share attributable to common shareholders:
Basic and Diluted (in shares)	42,481,027	38,503,944		27,306,258
Product [Member]
Revenue	$ 136,000	$ 101,913		$ 44,540
Costs and operating expenses:
Cost of goods and services	88,519	69,676		18,058
Service Revenue [Member]
Revenue	15,308	9,817		1,752
Costs and operating expenses:
Cost of goods and services	12,360	5,381		1,367
Rental Revenue [Member]
Revenue	10,451	7,426		1,795
Costs and operating expenses:
Cost of goods and services	$ 7,058	$ 7,051		$ 1,221

[1]2021 revenue includes product revenue related to Global Cooling from May 3, 2021 through December 31, 2021 and product revenue related to Sexton from September 1, 2021 through December 31, 2021.[2]2020 revenue includes service revenue related to SciSafe from October 1, 2020 through December 31, 2020.[3]The Consolidated Statements of Comprehensive (Loss) Income for the years ended December 31, 2021 and 2020 were adjusted by the impact to net (loss) income noted here. Comprehensive loss for the year ended December 31, 2021 is now reported at $9.2 million, reflecting an adjustment of $1.3 million, and was previously reported as $7.9 million. Comprehensive income for the year ended December 31, 2020 is now reported at $1.9 million, reflecting an adjustment of negative $684,000, and was previously reported as $2.7 million.

Consolidated Statements of Comp

Consolidated Statements of Comprehensive (Loss) Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020
Net (loss) income	$ (139,805)	$ (8,908)	[1]	$ 1,983	[1]
Other comprehensive loss - foreign currency translation adjustment, net of tax	(347)	(282)		0
Unrealized loss on available-for-sale securities, net of tax	(50)	0		0
Comprehensive (loss) income	$ (140,202)	$ (9,190)		$ 1,983

[1]The Consolidated Statements of Comprehensive (Loss) Income for the years ended December 31, 2021 and 2020 were adjusted by the impact to net (loss) income noted here. Comprehensive loss for the year ended December 31, 2021 is now reported at $9.2 million, reflecting an adjustment of $1.3 million, and was previously reported as $7.9 million. Comprehensive income for the year ended December 31, 2020 is now reported at $1.9 million, reflecting an adjustment of negative $684,000, and was previously reported as $2.7 million.

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	GCI Acquisition [Member] Preferred Stock [Member] Series A Preferred Stock [Member]	GCI Acquisition [Member] Common Stock [Member]	GCI Acquisition [Member] Additional Paid-in Capital [Member]	GCI Acquisition [Member] AOCI Attributable to Parent [Member]	GCI Acquisition [Member] Retained Earnings [Member]	GCI Acquisition [Member]	Sexton Acquisition [Member] Preferred Stock [Member] Series A Preferred Stock [Member]	Sexton Acquisition [Member] Common Stock [Member]	Sexton Acquisition [Member] Additional Paid-in Capital [Member]	Sexton Acquisition [Member] AOCI Attributable to Parent [Member]	Sexton Acquisition [Member] Retained Earnings [Member]	Sexton Acquisition [Member]	Preferred Stock [Member] Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2019													0	20,825,452
Balance at Dec. 31, 2019													$ 0	$ 21	$ 143,485	$ 0	$ (100,185)	$ 43,321
Stock issued as 2019 bonus payout													0	0	314	0	0	314
Stock-based compensation													$ 0	$ 0	5,981	0	0	5,981
Sale of common stock, net of costs (in shares)													0	7,856,012
Sale of common stock, net of costs													$ 0	$ 8	100,113	0	0	100,121
Common stock issued for services (in shares)													0	3,175
Common stock issued for services													$ 0	$ 0	60	0	0	60
Shares issued in acquisitions (in shares)													0	611,683
Shares issued in acquisitions													$ 0	$ 0	17,916	0	0	17,916
Stock option exercises (in shares)													0	777,496
Stock option exercises													$ 0	$ 1	1,471	0	0	1,472
Stock issued – on vested RSAs (in shares)													0	208,858
Stock issued – on vested RSAs													$ 0	$ 0	0	0	0	0
Cashless exercises of warrants (in shares)													0	2,747,970
Cashless exercises of warrants													$ 0	$ 3	33,108	0	0	33,111
Warrant exercises (in shares)													0	8,500
Warrant exercises													$ 0	$ 0	150	0	0	150
Net (loss) income													$ 0	$ 0	0	0	1,983	1,983	[1]
Balance (in shares) at Dec. 31, 2020													0	33,039,146
Balance at Dec. 31, 2020													$ 0	$ 33	302,598	0	(98,202)	204,429
Stock-based compensation													$ 0	$ 0	13,956	0	0	13,956
Shares issued in acquisitions (in shares)	0	6,636,470					0	530,502
Shares issued in acquisitions	$ 0	$ 7	$ 232,734	$ 0	$ 0	$ 232,741	$ 0	$ 0	$ 31,977	$ 0	$ 0	$ 31,977
Stock option exercises (in shares)													0	869,065
Stock option exercises													$ 0	$ 1	1,417	0	0	1,418
Stock issued – on vested RSAs (in shares)													0	672,290
Stock issued – on vested RSAs													$ 0	$ 1	0	0	0	1
Cashless exercises of warrants (in shares)													0	70,030
Cashless exercises of warrants													$ 0	$ 0	2,901	0	0	2,901
Net (loss) income													0	0	0	0	(8,908)	(8,908)	[1]
Fees incurred for registration filings													0	0	(186)	0	0	(186)
Foreign currency translation													$ 0	$ 0	0	(282)	0	(282)
Balance (in shares) at Dec. 31, 2021													0	41,817,503
Balance at Dec. 31, 2021													$ 0	$ 42	585,397	(282)	(107,110)	478,047
Stock-based compensation													$ 0	$ 0	25,334	0	0	25,334
Stock option exercises (in shares)													0	161,646
Stock option exercises													$ 0	$ 0	323	0	0	323
Stock issued – on vested RSAs (in shares)													0	788,952
Stock issued – on vested RSAs													$ 0	$ 1	(1)	0	0	0
Net (loss) income													0	0	0	0	(139,805)	(139,805)
Fees incurred for registration filings													0	0	(131)	0	0	(131)
Foreign currency translation													$ 0	$ 0	0	(397)	0	(397)
Stock issued as consideration for SciSafe earnout (in shares)													0	64,130
Stock issued as consideration for SciSafe earnout													$ 0	$ 0	817	0	0	817
Balance (in shares) at Dec. 31, 2022													0	42,832,231
Balance at Dec. 31, 2022													$ 0	$ 43	$ 611,739	$ (679)	$ (246,915)	$ 364,188

[1]The Consolidated Statements of Comprehensive (Loss) Income for the years ended December 31, 2021 and 2020 were adjusted by the impact to net (loss) income noted here. Comprehensive loss for the year ended December 31, 2021 is now reported at $9.2 million, reflecting an adjustment of $1.3 million, and was previously reported as $7.9 million. Comprehensive income for the year ended December 31, 2020 is now reported at $1.9 million, reflecting an adjustment of negative $684,000, and was previously reported as $2.7 million.

Consolidated Statements of Sh_2

Consolidated Statements of Shareholders' Equity (Parentheticals) - shares	12 Months Ended		36 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2022
Cashless warrant exercises (in shares)	79,100	3,871,405	3,879,905

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020
Cash flows from operating activities
Net (loss) income	$ (139,805,000)	$ (8,908,000)	[1]	$ 1,983,000	[1]
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities
Impairment of intangible assets	110,364,000	0		0
Depreciation	6,775,000	4,663,000		2,035,000
Amortization of intangible assets	9,697,000	8,202,000		3,033,000
Amortization of loan costs	18,000	121,000		0
Stock-based compensation	25,334,000	13,956,000		5,981,000
Non-cash lease expense	3,486,000	2,053,000		737,000
Deferred income tax benefit	(5,238,000)	(20,127,000)		(3,297,000)
Change in fair value of contingent consideration	(4,754,000)	2,875,000		1,575,000
Change in fair value of warrant liability	0	121,000		(3,601,000)
Change in fair value of investments	(697,000)	0		(1,319,000)
Accretion of investments	(447,000)	0		0
Gain on acquisition of Sexton Biotechnologies, Inc.	0	(6,451,000)		0
Stock issued for services	0	0		60,000
Loss on disposal of assets held for rent, net	773,000	609,000		365,000
Loss on disposal of property and equipment, net	745,000	482,000		0
Forgiveness of loans payable	0	(284,000)		0
Other	166,000	353,000		190,000
Change in operating assets and liabilities, net of effects of acquisitions
Accounts receivable, trade, net	(10,753,000)	(10,132,000)		(1,786,000)
Inventories	(6,559,000)	114,000		(629,000)
Prepaid expenses and other current assets	26,000	2,663,000		(50,000)
Accounts payable	414,000	2,018,000		(171,000)
Accrued expenses and other current liabilities	1,787,000	(3,936,000)		780,000
Sales taxes payable	1,526,000	1,412,000		759,000
Warranty liability	(1,086,000)	5,833,000		0
Other	(260,000)	(230,000)		0
Net cash used in operating activities	(8,488,000)	(4,593,000)		6,645,000
Cash flows from investing activities
Payments related to the acquisition of SciSafe, net of cash acquired				(14,947,000)
Cash acquired in acquisition of Global Cooling, Inc. and Sexton Biotechnologies, Inc.	0	1,559,000
Purchases of property and equipment	(10,385,000)	(8,385,000)		(1,961,000)
Deposits on property and equipment	0	0		(2,672,000)
Purchases of assets held for rent	(3,536,000)	(6,371,000)		(2,813,000)
Deposits on assets held for rent	0	0		(362,000)
Proceeds from sale of marketable securities	420,000	0		0
Maturities of marketable securities	8,500,000	0		0
Investment in available-for-sale securities	(53,116,000)	0		0
Proceeds from sale of equipment	0	5,000		35,000
Net cash used in investing activities	(58,117,000)	(13,192,000)		(24,715,000)
Cash flows from financing activities
Proceeds from term loan	20,000,000	0		0
Payments on term loan	(1,666,000)	0		0
Payments of contingent consideration	0	0		(483,000)
Fees paid related to issuance of common stock	(131,000)	(145,000)		0
Proceeds from line of credit	0	27,306,000		0
Payments on line of credit	0	(31,536,000)		0
Proceeds from exercise of common stock options	323,000	1,418,000		1,472,000
Proceeds from exercise of warrants	0	0		40,000
Other	(337,000)	(124,000)		(56,000)
Net cash provided by (used in) financing activities	16,316,000	(2,778,000)		102,078,000
Net decrease in cash, cash equivalents, and restricted cash	(50,289,000)	(20,563,000)		84,008,000
Cash, cash equivalents, and restricted cash – beginning of period	69,870,000	90,456,000		6,448,000
Effects of currency translation on cash, cash equivalents, and restricted cash	(108,000)	(23,000)		0
Cash, cash equivalents, and restricted cash – end of period	19,473,000	69,870,000		90,456,000
Non-cash investing and financing activities
Cashless exercise of warrants reclassified from warrant liability to common stock	0	2,901,000		33,111,000
Equipment acquired under operating leases	243,000	6,875,000		8,096,000
Equipment acquired under finance leases	0	440,000		0
Purchase of property and equipment not yet paid	478,000	197,000		0
Unrealized gains and losses on available-for-sale-securities	50,000	0		0
Reclassification of warrant liabilities to equity upon exercise	0	0		110,000
Stock issued as bonus consideration	0	0		314,000
Cash interest paid	586,000	452,000		0
Global Cooling, Inc. and Sexton Biotechnologies [Member]
Non-cash investing and financing activities
Stock issued as consideration	0	264,718,000		0
SciSafe [Member]
Non-cash investing and financing activities
Stock issued as consideration	817,000	0		17,916,000
Common Stock, 2020 [Member]
Cash flows from financing activities
Proceeds from sale of common stock, net of $6.2 million of costs in 2020	0	0		100,121,000
Fees paid related to issuance of common stock				(6,200,000)
Paycheck Protection Program CARES Act [Member]
Cash flows from financing activities
Proceeds from loans	0	0		2,175,000
Payments on loans	0	0		(2,175,000)
Equipment Loans [Member]
Cash flows from financing activities
Proceeds from loans	0	1,550,000		984,000
Payments on loans	(498,000)	(214,000)		0
Financed Insurance Premium [Member]
Cash flows from financing activities
Payments on financed insurance premium	(1,375,000)	(1,033,000)		0
IVexSol Preferred Stock Investment [Member]
Cash flows from investing activities
Investment	0	0		(1,000,000)
PanTHERA Cryosolutions Investment [Member]
Cash flows from investing activities
Investment	$ 0	$ 0		$ (995,000)

[1]The Consolidated Statements of Comprehensive (Loss) Income for the years ended December 31, 2021 and 2020 were adjusted by the impact to net (loss) income noted here. Comprehensive loss for the year ended December 31, 2021 is now reported at $9.2 million, reflecting an adjustment of $1.3 million, and was previously reported as $7.9 million. Comprehensive income for the year ended December 31, 2020 is now reported at $1.9 million, reflecting an adjustment of negative $684,000, and was previously reported as $2.7 million.

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parentheticals) $ in Thousands	12 Months Ended
	Dec. 31, 2020 USD ($)
Stock issuance costs	$ 0
Common Stock, 2020 [Member]
Stock issuance costs	$ 6,200

Note 1 - Organization and Signi

Note 1 - Organization and Significant Accounting Policies	12 Months Ended
Note 1 - Organization and Significant Accounting Policies	Dec. 31, 2022
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	1. Organization and significant accounting policies Business BioLife Solutions, Inc. (“BioLife”, “us”, “we”, “our”, or the “Company”) is a developer, manufacturer, and supplier of a portfolio of bioproduction tools and services including proprietary biopreservation media, automated thawing devices, cloud-connected shipping containers, ultra-low temperature mechanical freezers, cryogenic and controlled rate freezers, and biological and pharmaceutical materials storage. Our CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. These novel biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. Our Sexton cell processing product line includes human platelet lysates (“hPL”) for cell expansion, reducing risk and improving downstream performance over fetal bovine serum, human serum, and other chemically defined media, CellSeal cryogenic vials that are purpose-built rigid containers used in cell and gene therapy (“CGT”) that can be filled manually or with high throughput systems, and automated cell processing machines that bring multiple processes traditionally performed by manual techniques under a higher level of control to protect therapies from loss or contamination. Our ThawSTAR product line is comprised of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. These products help administer temperature-sensitive biologic therapies to patients by standardizing the thawing process and reducing the risks of contamination and overheating, which are inherent with the use of traditional water baths. Our cryogenic freezer technology provides for controlled rate freezing and cryogenic storage of biologic materials. Our ultra-low temperature mechanical freezers allow biological materials and vaccines to be stored at temperatures which range from negative 20℃ 86℃. Use of estimates The preparation of financial statements in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions by management affect the Company’s allowance for doubtful accounts, the net realizable value of inventory, fair value of warrant liability, sales tax liabilities, valuation of market based awards, valuations and purchase price allocations related to investments and business combinations, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, amortization methods and periods, warranty reserves, certain accrued expenses, share-based compensation, contingent consideration from business combinations, and the provision for income taxes. The Company regularly assesses these estimates; however, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances. Basis of presentation The Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries, SAVSU Technologies, Inc. (“SAVSU”), Arctic Solutions, Inc. doing business as CBS, SciSafe (acquired on October 1, 2020), May 3, 2021), September 1, 2021). All long-lived assets are maintained in the United States of America and the Netherlands. Foreign currency translation The Company translates balance sheet and income statement items into U.S. dollars. For the Company’s subsidiaries that operate in a local currency functional environment, all assets and liabilities are translated into U.S. dollars using current exchange rates at the balance sheet date; revenue and expenses are translated using quarterly exchange rates which approximate to average exchange rates in effect during each period. Resulting translation adjustments are reported as a separate component of accumulated other comprehensive (loss) income in shareholders' equity. Segment reporting The Company views its operations and makes decisions regarding how to allocate resources and manages its business as one one Revenue recognition To determine revenue recognition for contractual arrangements that we determine are within the scope of Financial Accounting Standards Board (“FASB”) Topic 606, Revenue from Contracts with Customers five five may not 30 90 December 31, 2022, The Company primarily recognizes product revenues, service revenues, and rental revenues. Product revenues are generated from the sale of biopreservation media, ThawSTAR, and freezer products. We recognize product revenue, including shipping and handling charges billed to customers, at a point in time when we transfer control of our products to our customers, which is upon shipment for substantially all transactions. Shipping and handling costs are classified as part of cost of product revenue in the Consolidated Statement of Operations. Service revenues are generated from the storage of biological and pharmaceutical materials. We recognize service revenues over time as services are performed or ratably over the contract term. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount method, depending on the facts and circumstances relative to the contract. When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in paragraph 606 10 32 18, not one None December 31, 2022. The Company also generates revenue from the leasing of our property, plant, and equipment, operating right-of-use assets, and evo cold chain systems to customers pursuant to service contracts or rental arrangements entered into with the customer. Revenue from these arrangements is not 606 842, Lease The Company enters into various customer service agreements (collectively, “Service Contracts”) with customers to provide biological and pharmaceutical storage services. In certain of these Service Contracts, the property, plant, and equipment or operating right-of-use assets used to store a customer’s product are used only for the benefit of one may not The Company has assessed its Service Contracts and concluded that certain of the contracts for the storage of customer products met the criteria to be considered a leasing arrangement (“Embedded Leases”), with the Company as the lessor. The specific Service Contracts that met the criteria were those that provided a single customer with the ability to substantially direct the use of the Company’s property, plant, and equipment or operating right-of-use assets. Under ASC 842, None None Embedded Leases may Total bioproduction tools and services revenue for the years ended December 31, 2022, 2021, 2020 Year Ended December 31, (In thousands, except percentages) 2022 2021 2020 Product revenue Freezer and thaw $ 66,682 $ 56,620 $ 13,548 Cell processing 68,509 44,965 30,946 Storage and cold chain services 809 328 46 Service revenue Freezer and thaw 74 - - Storage and cold chain services 15,234 9,817 1,752 Rental revenue Storage and cold chain services 10,451 7,426 1,795 Total revenue $ 161,759 $ 119,156 $ 48,087 ( 1 2021 May 3, 2021 December 31, 2021 September 1, 2021 December 31, 2021. ( 2 2020 October 1, 2020 December 31, 2020. The following table includes estimated rental revenue expected to be recognized in the future related to embedded leases as well as estimated service revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting periods. The Company elected not one 2014 09, Revenue from Contracts with Customers not one December 31, 2022. The balances in the table below are partially based on judgments involved in estimating future orders from customers subject to the exercise of material rights pursuant to respective contracts: (In thousands) 2023 2024 Total Rental revenue $ 3,735 $ 900 $ 4,635 Service revenue $ 200 $ 10 $ 210 Risks and uncertainties COVID- 19 Our domestic and international operations have been and continue to be affected by the ongoing global pandemic of a novel strain of coronavirus (“COVID- 19” During year ended December 31, 2021, 19. December 31, 2022, December 31, 2021. December 31, 2022. We cannot be assured that a continued or prolonged global pandemic will not 19 19. The Company reviews capital and amortizing intangible assets (long-lived assets) for impairment on an annual basis or whenever events or changes in circumstances indicate that the carrying amount may not 19 June 30, 2020 19. As a result of the Company’s outlook for revenue from the ThawSTAR and freezer product lines, estimated undiscounted cash flow projections were developed to determine if any impairment of the related intangible assets was warranted. After conducting such review, the Company determined that there was no June 30, 2020. 19 The Company revised the revenue projections for the ThawSTAR and freezer product lines in the second June 30, 2020 December 31, 2020 two no December 31, 2020. June 30, 2020, December 31, 2020 December 31, 2020. The Company may 19 third Any disruption and volatility in the global capital markets as a result of the pandemic may 19 not The ultimate extent to which the COVID- 19 19 On April 20, 2020, April 29, 2020. Earnings per share The Company considers its unexercised warrants and unvested restricted shares, which contain non-forfeitable rights to dividends, participating securities, and includes such participating securities in its computation of earnings per share pursuant to the two two two The following table presents computations of basic and diluted earnings per share under the two Year Ended December 31, (In thousands, except share and earnings per share data) 2022 2021 2020 Basic earnings (loss) per common share Numerator: Net (loss) income $ (139,805 ) $ (8,908 ) $ 1,983 Amount attributable to unvested restricted shares - - (100 ) Amount attributable to warrants outstanding - - (61 ) Net (loss) income allocated to common shareholders (139,805 ) (8,908 ) 1,822 Denominator: Weighted-average common shares issued and outstanding 42,481,027 38,503,944 27,306,258 Basic (loss) earnings per common share $ (3.29 ) $ (0.23 ) $ 0.07 Diluted earnings (loss) per common share Numerator: Net (loss) income $ (139,805 ) $ (8,908 ) $ 1,983 Amount attributable to warrants - - (14 ) Less: gain related to change in fair value of warrants - - (3,601 ) Net loss allocated to common shareholders (139,805 ) (8,908 ) (1,632 ) Denominator: Weighted-average common shares issued and outstanding 42,481,027 38,503,944 27,306,258 Diluted loss per common share $ (3.29 ) $ (0.23 ) $ (0.06 ) The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive: Year Ended December 31, 2021 2020 Stock options and restricted stock awards 1,637,745 2,131,794 Warrants 18,204 1,499,953 Total 1,655,949 3,631,747 Cash, cash equivalents, and restricted cash Cash equivalents consist primarily of interest-bearing money market accounts. We consider all highly liquid debt instruments purchased with an initial maturity of three may not Restricted cash consists entirely of amounts that will be recovered from escrow in relation to the acquisition of SciSafe. The restricted cash is short term in nature, as the Company anticipates to receive the funds within one The following is a summary of the Company’s cash, cash equivalents, and restricted cash total as presented in the Company’s Consolidated Statements of Cash Flows for the years ended December 31, 2022 2021. (In thousands) 2022 2021 Cash and cash equivalents $ 19,442 $ 69,860 Restricted cash 31 10 Total cash, cash equivalents, and restricted cash $ 19,473 $ 69,870 Available-for-sale securities Available-for-sale securities consist of U.S. government securities, corporate debt securities, and other debt securities. Management classifies investments at the time of purchase and reevaluates such classification at each balance sheet date. Investments with maturities beyond one may Inventories Inventories relate to the Company’s cell and gene therapy products. The Company values biopreservation media inventory at cost or, if lower, net realizable value, using the specific identification method. All other inventory is valued at cost or, if lower, net realizable value, using the first first no Accounts receivable Accounts receivable consist of short-term amounts due from our customers (generally 30 90 Accounts receivable are stated at principal amount, do not Equity investments We periodically invest in securities of private companies to promote business and strategic objectives. These investments are measured and recorded as follows: Non-marketable equity securities are equity securities without a readily determinable fair value. As of December 31, 2022, 1 2 December 31, 2021, 1 2 As of December 31, 2022, September 1, 2021. December 31, 2020, not zero December 31, 2022, 2021, 2020, November 2020, 1 2 In November 2020, June 2021, first As of December 31, 2022, no Property and equipment Property and equipment are stated at cost and are depreciated using the straight-line method over estimated useful lives of three ten Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that their net book value may not may no December 31, 2022, 2021, 2020. Assets held for rent Assets held for rent are carried at cost less accumulated depreciation. These assets consist of dedicated storage space, evo shippers and related components in production shippers complete and ready to be deployed and placed in service upon a customer order, shippers in the process of being assembled, and components available to build shippers. Assets utilized to provide dedicated storage space are depreciated over their applicable useful lives once placed in service. Shippers are depreciated over a useful life of three Our customers rent assets per a rental agreement. Each agreement provides for fixed monthly rent. Rental revenue and fees are recognized over the rental term on a straight-line basis. We retain the ownership of the assets rented. At the end of the rental agreement, the customer returns the asset to the Company. Assets held for rent are reviewed for impairment whenever events or changes in circumstances indicate that their net book value may not may December 31, 2022, 2021, 2020. Lease accounting We determine if an arrangement is a lease at inception. Where an arrangement is a lease, we determine if it is an operating lease or a financing lease. At lease commencement, we record a lease liability and corresponding right-of-use (“ROU”) asset. Lease liabilities represent the present value of our future lease payments over the expected lease term which includes options to extend or terminate the lease when it is reasonably certain those options will be exercised. The present value of our lease liability is determined using our incremental collateralized borrowing rate at lease inception. ROU assets represent our right to control the use of the leased asset during the lease and are recognized in an amount equal to the lease liability for leases with an initial term greater than 12 We elected to apply the practical expedient for short-term leases and accordingly do not twelve Warranty Our standard warranty terms typically extend between one seven Income taxes We account for income taxes using an asset and liability method which generally requires recognition of deferred tax assets and liabilities for the expected future tax effects of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are recognized for the future tax effects of differences between tax bases of assets and liabilities, and financial reporting amounts, based upon enacted tax laws and statutory rates applicable to the periods in which the differences are expected to affect taxable income. We evaluate the likelihood of realization of deferred tax assets and provide an allowance where, in management’s opinion, it is more likely than not not We determine any uncertain tax positions based on a determination of whether and how much of a tax benefit taken in the Company’s tax filings or positions is more likely than not Judgment is applied in the determination of the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. As of December 31, 2022, Advertising Advertising costs are expensed as incurred and totaled $768,000, $552,000, and $167,000 for the years ended December 31, 2022, 2021, 2020, Concentrations of risk During the years ended December 31, 2022 2021, December 31, 2020, No 10% Year Ended December 31, Revenue by major product 2022 2021 2020 CryoStor 36 % 33 % 60 % 780XLE Freezer 22 % 22 % - % In the years ended December 31, 2022, 2021, 2020, no 10% The following table represents the Company’s total revenue by geographic area (based on the location of the customer): Year Ended December 31, Revenue by customers geographic locations 2022 2021 2020 United States 72 % 78 % 73 % Canada 17 % 7 % 13 % Europe, Middle East, Africa (EMEA) 7 % 14 % 12 % Other 4 % 1 % 2 % Total revenue 100 % 100 % 100 % The following table represents the Company’s long-lived assets by geographic area as of December 31: (In thousands) 2022 2021 United States $ 42,829 $ 40,708 Netherlands 5,437 5,903 Total $ 48,266 $ 46,611 As of December 31, 2022, two December 31, 2021, two No 10% As of December 31, 2022, one December 31, 2021, No 10% Research and development Research and development costs are expensed as incurred. Stock-based compensation We measure and record compensation expense using the applicable accounting guidance for share-based payments related to stock options, time-based restricted stock, market-based restricted stock awards and performance-based restricted stock awards granted to our directors and employees. The fair value of stock options, including performance awards, without a market-based condition is determined by using the Black-Scholes option-pricing model. The fair value of restricted stock awards with a market condition is estimated at the date of grant using the Monte Carlo Simulation model. The Black-Scholes and Monte Carlo Simulation valuation models incorporate assumptions as to stock price volatility, the expected life of options or awards, a risk-free interest rate and dividend yield. The fair value of restricted stock, including performance awards, without a market condition is estimated using the current market price of our common stock on the date of grant. We expense stock-based compensation for stock options, restricted stock awards, and performance awards over the requisite service period. For awards with only a service condition, we expense stock-based compensation using the straight-line method over the requisite service period for the entire award. For awards with a market condition, we expense the grant date fair value over the vesting period regardless of the value that the award recipients ultimately receive. We have, from time to time, modified the terms of restricted stock awards awarded to employees. We account for the incremental increase in the fair value over the original award on the date of the modification as an expense for vested awards or over the remaining service (vesting) period for unvested awards. The incremental compensation cost is the excess of the fair value of the modified award on the date of modification over the fair value of the original award immediately before the modification. Business combinations, goodwill, and intangible assets Business combinations The Company accounts for business acquisitions using the acquisition method as required by FASB ASC Topic 805, Business Combinations The Company’s identifiable assets acquired and liabilities, including identified intangible assets, assumed in a business combination are recorded at their acquisition date fair values. The valuation requires management to make significant estimates and assumptions, especially with respect to long-lived and intangible assets. Critical estimates in valuing intangible assets include, but are not ● future expected cash flows, including revenue and expense projections; ● discount rates to determine the present value of recognized assets and liabilities and; ● revenue volatility to determine contingent consideration using option pricing models Goodwill is calculated as the excess of the acquisition price over the fair value of net assets acquired, including the amount assigned to identifiable intangible assets. Acquisition-related costs, including advisory, legal, accounting, valuation, and other costs, are expensed in the periods in which these costs are incurred. The results of operations of an acquired business are included in the consolidated financial statements beginning at the acquisition date. The Company estimates the acquisition date fair value of the acquisition-related contingent consideration using various valuation approaches, including option pricing models, as well as significant unobservable inputs, reflecting the Company’s assessment of the assumptions market participants would use to value these liabilities. The fair value of the contingent consideration is remeasured each reporting period. During the measurement period, which may one Goodwill Goodwill represents the excess of the purchase price over the net amount of identifiable assets acquired and liabilities assumed in a business combination measured at fair value. Goodwill is not fourth may first not 350, Intangibles Goodwill and Other not 50 not not not not one fourth 2022. no Intangible assets Intangible assets with a definite life are amortized over their estimated useful lives using the straight-line method and the amortization expense is recorded within intangible asset amortization in the Consolidated Statements of Operations. If the estimate of a definite-lived intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset is amortized prospectively over the revised remaining useful life. Definite-lived intangible assets and their related estimated useful lives are reviewed at least annually to determine if any adverse conditions exist that would indicate the carrying value of these assets may not June 30, 2022 October 1, 2022, 11 Indefinite-lived intangibles are carried at the initially recorded fair value less any recognized impairment. In-process research and development (“IPR&D”) is initially capitalized at fair value as an intangible asset with an indefinite life. When the IPR&D project is complete, it is reclassified as a definite-lived intangible asset and is amortized over its estimated useful life. If an IPR&D project is abandoned, a charge would be recorded for the value of the related intangible asset to our Consolidated Statement of Operations in the period it is abandoned. Indefinite-lived intangibles are tested annually for impairment. Impairment assessments are conducted more frequently if certain conditions exist, including a change in the competitive landscape, any internal decisions to pursue new or different technology strategies, a loss of a significant customer, or a significant change in the marketplace, including changes in the prices paid for the Company’s products or changes in the size of the market for the Company’s products. If impairment indicators are present, the Company determines whether the underlying intangible asset is recoverable through estimated future undiscounted cash flows. If the asset is not second 2022, 2021. June 30, 2022 October 1, 2022, 11 Certain warrants which have features that may Warrants that include cash settlement features are recorded as liabilities at their estimated fair value at the date of issuance and are remeasured at fair value each reporting period with the increase or decrease in fair value recorded in the Consolidated Statements of Operations. The warrants are measured at estimated fair value using the Black Scholes valuation model, which is based, in part, upon inputs for which there is little or no zero December 31, 2022, no Recent accounting pronouncements In June 2022, No. 2022 03, Fair Value Measurements (Topic 820 820” 2022 03 1 820, 2 3 820. 2022 03 not not December 15, 2023, 2022 03. not In March 2022, No. 2022 02 Financial Instruments-Credit Losses (Topic 326 2022 02 2022 02 326 2022 02 December 15, 2022 not In November 2021, No. 2021 10, Government Assistance (Topic 832 December 15, 2023, In October 2021, No. 2021 08, Business Combinations (Topic 805 Accounting for Contract Assets and Contract Liabilities from Contracts with Customers Revenue from Contracts with Customers (Topic 606 606 2021 08 December 15, 2022, not In March 2020, No. 2020 04, Reference Rate Reform (Topic 848 2020 04 January 2021, 2021 01, Reference Rate Reform Scope December 2022, 2022 06, Reference Rate Reform Deferral of the Sunset Date of Topic 848 2020 04 December 31, 2024. not In June 2016, No. 2016 13, Financial Instruments Credit Losses (Topic 326 2016 13 November 19, 2019, 2016 13 December 15, 2023,

Note 2 - Revision of Previously

Note 2 - Revision of Previously Issued Consolidated Financial Statements	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Error Correction [Text Block]	2. Correction of immaterial errors During the fourth 2022, December 31, 2019 not not not December 31, 2021 2020 The following tables represent the adjustments to our Consolidated Statements of Operations and Consolidated Statements of Cash Flows for the years ended December 31, 2021 2020, December 31, 2021 250. The effect of the adjustments to our Consolidated Balance Sheet as of December 31, 2021 December 31, 2021 As reported Adjustment As corrected Prepaid expenses and other current assets $ 4,427 $ 229 $ 4,656 Total current assets 125,859 229 126,088 Total assets 554,057 229 554,286 Accrued expenses and other current liabilities (1) 7,142 (272 ) 6,870 Sales taxes payable - 2,591 2,591 Total current liabilities 40,381 2,319 42,700 Total liabilities 73,920 2,319 76,239 Accumulated deficit (2) (105,020 ) (2,090 ) (107,110 ) Total shareholders’ equity 480,137 (2,090 ) 478,047 Total liabilities and shareholders’ equity 554,057 229 554,286 ( 1 In the prior year Consolidated Balance Sheet as of the year ended December 31, 2021, ( 2 The impact of the error on Accumulated deficit in our Consolidated Balance Sheet as of the year ended December 31, 2019 $100.2 The effect of the adjustments to our Consolidated Statements of Operations for the years ended December 31, 2021 2020 Years Ended December 31, 2021 and 2020 2021 As reported Adjustment As corrected General and administrative $ 32,448 $ 1,220 $ 33,668 Total operating expenses 153,096 1,220 154,316 Operating loss (33,940 ) (1,220 ) (35,160 ) Interest expense (432 ) (53 ) (485 ) Total other income, net 6,187 (53 ) 6,134 Loss before income tax benefit (27,753 ) (1,273 ) (29,026 ) Net loss (1) (7,635 ) (1,273 ) (8,908 ) Net loss per basic share (0.20 ) (0.03 ) (0.23 ) Net loss per diluted share (0.20 ) (0.03 ) (0.23 ) 2020 General and administrative 14,607 666 15,273 Total operating expenses 53,662 666 54,328 Operating loss (5,575 ) (666 ) (6,241 ) Interest income 58 (18 ) 40 Total other income, net 4,978 (18 ) 4,960 Loss before income tax benefit (597 ) (684 ) (1,281 ) Net income (1) 2,667 (684 ) 1,983 Net income attributable to common shareholders - Basic 2,450 (628 ) 1,822 Net loss attributable to common shareholders - Diluted (954 ) (678 ) (1,632 ) Net income per basic share 0.09 (0.02 ) 0.07 Net loss per diluted share (0.03 ) (0.03 ) (0.06 ) ( 1 The Consolidated Statements of Comprehensive (Loss) Income for the years ended December 31, 2021 2020 December 31, 2021 December 31, 2020 The effect of the adjustments to our Consolidated Statements of Cash Flows for the years ended December 31, 2021 2020 Years Ended December 31, 2021 and 2020 2021 As reported Adjustment As corrected Net loss $ (7,635 ) $ (1,273 ) $ (8,908 ) Prepaid expenses and other current assets 2,802 (139 ) 2,663 Sales taxes payable - 1,412 1,412 2020 Net income 2,667 (684 ) 1,983 Prepaid expenses and other current assets 25 (75 ) (50 ) Sales taxes payable - 759 759 All accompanying footnotes reflect corrected balances presented in the tables above.

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurement	12 Months Ended
Note 3 - Fair Value Measurement	Dec. 31, 2022
Notes to Financial Statements
Fair Value Disclosures [Text Block]	3. Fair value measurement In accordance with FASB ASC Topic 820, Fair Value Measurements and Disclosures 820” 1 2 2 3 1: Organization and Significant Accounting Policies 820 820 three Level 1 Level 2 1 not Level 3 For the investment in iVexSol convertible debt that was converted to Series A- 1 November 2020, 3 September 2019 The fair value of the SciSafe contingent consideration liability was initially valued based on unobservable inputs using a Monte Carlo simulation. These inputs included the estimated amount and timing of projected future revenue, a discount rate of 4.5%, a risk-free rate of approximately 0.20%, asset volatility of 60%, and revenue volatility of 15%. Significant changes in any of those inputs in isolation would result in significant changes in fair value measurement. Generally, changes used in the assumptions for projected future revenue and revenue volatility would be accompanied by a directionally similar change in the fair value measurement. Conversely, changes in the discount rate would be accompanied by a directionally opposite change in the related fair value measurement. However, due to the contingent consideration having a maximum payout amount, changes in these assumptions would not December 31, 2022, December 31, 2022 2021 December 31, 2022 2021, For the warrant liability, the significant Level 3 March 25, 2021. December 31, 2020, not March 25, 2021, There were no December 31, 2022 not The following tables set forth the Company’s financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2022 2021, three (In thousands) As of December 31, 2022 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market accounts $ 11,416 $ - $ - $ 11,416 Available-for-sale securities: U.S. government securities 15,051 - - 15,051 Corporate debt securities - 26,047 - 26,047 Other debt securities - 3,494 - 3,494 Total 26,467 29,541 - 56,008 Liabilities: Contingent consideration - business combinations - - 4,456 4,456 Debt - 25,607 - 25,607 Total $ - $ 25,607 $ 4,456 $ 30,063 As of December 31, 2021 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 63,873 $ - $ - $ 63,873 Total 63,873 - - 63,873 Liabilities: Contingent consideration - business combinations - - 10,027 10,027 Total $ - $ - $ 10,027 $ 10,027 There have been no The following table presents the changes in fair value of contingent consideration liabilities which are measured using Level 3 December 31, 2022, 2021, 2020: Year Ended December 31, (In thousands) 2022 2021 2020 Beginning balance as of December 31, 2021, 2020, and 2019 $ 10,027 $ 7,152 1,914 Additions - - 3,663 Change in fair value recognized in net (loss) income (4,754 ) 2,875 1,575 Payment of contingent consideration earned (817 ) - - Ending balance $ 4,456 $ 10,027 $ 7,152 The following table presents the changes in fair value of warrant liabilities which are measured using Level 3 December 31, 2021 2020: (In thousands) 2021 2020 Beginning balance as of December 31, 2020 and 2019 $ 2,780 39,602 Exercised warrants (2,901 ) (33,221 ) Change in fair value recognized in net (loss) income 121 (3,601 ) Ending balance $ - $ 2,780 There was no December 31, 2022.

Note 4 - Investments

Note 4 - Investments	12 Months Ended
Note 4 - Investments	Dec. 31, 2022
Notes to Financial Statements
Investment [Text Block]	4. Investments Available-for-sale securities The Company’s portfolio of available-for-sale marketable securities consists of the following: December 31, 2022 Amortized Gross unrealized Estimated (In thousands) Cost Gains Losses Fair Value Available-for-sale securities, current portion U.S. government securities $ 15,087 $ 1 $ 37 $ 15,051 Corporate debt securities 26,057 6 16 26,047 Other debt securities 2,169 - 7 2,162 Total short-term 43,313 7 60 43,260 Available-for-sale securities, long-term Other debt securities 1,329 3 - 1,332 Total marketable securities $ 44,642 $ 10 $ 60 $ 44,592 Amortized Estimated (In thousands) Cost Fair Value Due in one year or less $ 43,313 $ 43,260 Due after one year through five years 1,329 1,332 Total $ 44,642 $ 44,592 There were no December 31, 2021. Equity investments The Company periodically invests in non-marketable equity securities of private companies without a readily determinable fair value to promote business and strategic objectives. These securities included Series A- 1 2 December 31, 2022 December 31, 2021, December 31, 2022 December 31, 2021.

Note 5 - Inventories

Note 5 - Inventories	12 Months Ended
Note 5 - Inventories	Dec. 31, 2022
Notes to Financial Statements
Inventory Disclosure [Text Block]	5. Inventories Inventories consist of the following as of December 31, 2022 2021: (In thousands) 2022 2021 Raw materials $ 20,950 $ 17,252 Work in progress 5,680 5,015 Finished goods 8,274 6,078 Total $ 34,904 $ 28,345

Note 6 - Leases

Note 6 - Leases	12 Months Ended
Note 6 - Leases	Dec. 31, 2022
Notes to Financial Statements
Lessee, Leases [Text Block]	6. Leases We have various operating lease agreements for office space, warehouses, manufacturing, and production locations as well as vehicles and other equipment. Our real estate leases have remaining lease terms of one eight not one five one five Our financing leases relate to research equipment, machinery, and other equipment. The table below presents certain information related to the weighted average discount rate and weighted average remaining lease term for the Company’s leases as of December 31, 2022 2021: 2022 2021 Weighted average discount rate - operating leases 4.2 % 3.8 % Weighted average discount rate - finance leases 6.1 % 6.1 % Weighted average remaining lease term in years - operating leases 7.2 7.8 Weighted average remaining lease term in years - finance leases 2.0 3.0 The components of lease expense for the years ended December 31, 2022, 2021, 2020 Year Ended December 31, (In thousands) 2022 2021 2020 Operating lease costs $ 3,701 $ 2,817 $ 839 Short-term lease costs 2,141 1,727 277 Total operating lease costs 5,842 4,544 1,116 Variable lease costs 1,104 749 357 Total lease expense $ 6,946 $ 5,293 $ 1,473 Maturities of our lease liabilities as of December 31, 2022 (In thousands) Operating Leases Financing Leases 2023 $ 3,448 $ 171 2024 3,089 101 2025 2,649 28 2026 2,267 2 2027 2,242 - Thereafter 6,927 - Total lease payments 20,622 302 Less: interest (2,800 ) (18 ) Total present value of lease liabilities $ 17,822 $ 284

Note 7 - Assets Held for Rent

Note 7 - Assets Held for Rent	12 Months Ended
Note 7 - Assets Held for Rent	Dec. 31, 2022
Notes to Financial Statements
Assets Held For Rent [Text Block]	7. Assets held for rent Assets held for rent consist of the following as of December 31, 2022 2021: (In thousands) 2022 2021 Shippers placed in service $ 7,671 $ 5,645 Fixed assets held for rent 4,686 4,040 Accumulated depreciation (4,952 ) (2,272 ) Net 7,405 7,413 Shippers and related components in production 1,659 2,396 Total $ 9,064 $ 9,809 Shippers and related components in production include shippers complete and ready to be deployed and placed in service upon a customer order, shippers in the process of being assembled, and components available to build shippers. We recognized $3.5 million, $1.9 million, and $671,000 in depreciation expense related to assets held for rent during the years ended December 31, 2022, 2021, 2020,

Note 8 - Property and Equipment

Note 8 - Property and Equipment	12 Months Ended
Note 8 - Property and Equipment	Dec. 31, 2022
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	8. Property and equipment Property and equipment consist of the following as of December 31, 2022 2021: (In thousands) 2022 2021 Property and equipment Leasehold improvements $ 5,249 $ 3,840 Furniture and computer equipment 1,908 1,861 Manufacturing and other equipment 20,557 16,675 Construction in-progress 5,095 2,022 Subtotal 32,809 24,398 Less: Accumulated depreciation (9,171 ) (6,741 ) Net property and equipment $ 23,638 $ 17,657 Depreciation expense for property and equipment was $3.3 million, $2.9 million, and $1.4 million for the years ended December 31, 2022, 2021, 2020,

Note 9 - Accrued Expenses and O

Note 9 - Accrued Expenses and Other Current Liabilities	12 Months Ended
Note 9 - Accrued Expenses and Other Current Liabilities	Dec. 31, 2022
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	9. Accrued expenses and other current liabilities Accrued expenses and other current liabilities consist of the following as of December 31, 2022 2021: (In thousands) 2022 2021 Accrued expenses $ 3,128 $ 1,656 Accrued taxes 975 27 Accrued compensation 5,080 4,351 Deferred revenue, current 548 814 Other 51 22 Total accrued expenses and other current liabilities $ 9,782 $ 6,870

Note 10 - Warranty Reserve Liab

Note 10 - Warranty Reserve Liability	12 Months Ended
Note 10 - Warranty Reserve Liability	Dec. 31, 2022
Notes to Financial Statements
Product Warranty Disclosure [Text Block]	10. Warranty reserve liability We reserve estimated exposures on known claims, as well as on a portion of anticipated claims, for product warranty and rework cost, based on historical product liability claims. Claim costs are deducted from the accrual when paid. Factors that could have an impact on the warranty accrual in any given period include the following: changes in manufacturing quality, changes in product costs, changes in product mix and any significant changes in sales volume. A rollforward of our warranty liability is as follows: (In thousands) 2022 2021 2020 Beginning balance as of December 31, 2021, 2020, and 2019 $ 9,398 $ 212 $ 191 Warranty reserve acquired in the acquisition of Global Cooling - 3,353 - Provision for warranties⁽¹⁾ 4,463 10,989 137 Settlements of warranty claims⁽¹⁾ (5,549 ) (5,156 ) (116 ) Ending Balance 8,312 9,398 212 ( 1 Both the Provision for warranties and Settlements of warranty claims balances include reclassifications of $1.6 million and $1.1 million for the years ended December 31, 2022 2021,

Note 11 - Goodwill and Intangib

Note 11 - Goodwill and Intangible Assets	12 Months Ended
Note 11 - Goodwill and Intangible Assets	Dec. 31, 2022
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	11. Goodwill and intangible assets Goodwill The following table represents the changes in the carrying value of goodwill for the years ended December 31, 2022 2021: (In thousands) Goodwill Balance as of December 31, 2020 $ 58,449 Goodwill related to Global Cooling acquisition 137,822 Goodwill related to Sexton acquisition 28,470 Balance as of December 31, 2022 and 2021 224,741 Intangible assets Intangible assets, net consisted of the following as of December 31, 2022 2021: (In thousands, except weighted average useful life) December 31, 2022 Intangible assets: Gross Carrying Value Accumulated Amortization Net Carrying Value Weighted Average Useful Life (in years) Customer Relationships $ 11,288 $ (3,993 ) $ 7,295 9.3 Tradenames 13,731 (4,323 ) 9,408 12.8 Technology - acquired 27,892 (12,796 ) 15,096 4.9 Non-compete agreements 1,187 (898 ) 289 2.0 Total intangible assets $ 54,098 $ (22,010 ) $ 32,088 8.2 December 31, 2021 Intangible assets: Gross Carrying Value Accumulated Amortization Net Carrying Value Weighted Average Useful Life (in years) Customer Relationships $ 17,516 $ (1,776 ) $ 15,740 10.3 Tradenames 35,574 (2,306 ) 33,268 13.8 Technology - acquired 41,942 (7,789 ) 34,153 5.9 Non-compete agreements 1,990 (442 ) 1,548 3.0 In-process research and development⁽¹⁾ 67,440 - 67,440 N/A Total intangible assets $ 164,462 $ (12,313 ) $ 152,149 9.8 ( 1 In-process R&D represents the fair value of incomplete research and development that has not second fourth December 31, 2022. Impairment expense for both finite and indefinite-lived intangible assets was $110.4 million, zero zero December 31, 2022, 2021, 2020, December 31, 2022, 2021, 2020, December 31, 2022, (In thousands) For the Years Ending December 31, Estimated Amortization Expense 2023 $ 5,431 2024 4,606 2025 4,434 2026 4,136 2027 3,382 Thereafter 10,099 Total $ 32,088 Impairment testing as of June 30, 2022 In the six June 30, 2022, July 2022, three June 30, 2022 To assess any potential impairment of goodwill, the Company compared the carrying value of its single reporting unit against its market capitalization, noting that the market capitalization exceeded the carrying value. As such, goodwill was not June 30, 2022. The abandonment of the aforementioned in-process research and development project resulted in an $8.0 million non-cash impairment charge during the three June 30, 2022 Intangible asset impairment charges In order to determine the fair value of our in-process research and development intangible assets not three June 30, 2022 Intangible asset impairment charges In order to determine the fair value of the acquired technology, customer relationships, tradename, and non-compete definite-lived intangible assets, the Company utilized the excess earnings approach, distributor method, relief from royalty method, and with and without approach, respectively. The key assumptions associated with determining the estimated fair value include (i) the amount and timing of projected future cash flows (including revenue and expenses), (ii) the discount rate selected to measure the risks inherent in the future cash flows, (iii) the assessment of the asset’s life cycle, and (iv) the competitive trends impacting the asset. As a result of the analysis, we recognized non-cash impairment charges of $3.5 million, $1.5 million, $5.9 million, and $4,000 during the period ended June 30, 2022 Intangible asset impairment charges Impairment Testing as of October 1, 2022 The Company annually performs an impairment assessment as of October 1. not October 1, 2022. In order to determine the fair value of our indefinite-lived intangible assets acquired from Global Cooling, which included an in-process research and development project, the Company utilized a discounted cash flow analysis. The key assumptions associated with determining the estimated fair value include projected future revenue growth rates, earnings before interest, taxes, depreciation and amortization ("EBITDA") margins, the terminal growth rate, and the discount rate. As a result of the changes in these assumptions, we recognized a $8.5 million non-cash impairment charge during the year-ended December 31, 2022 Intangible asset impairment charges October 1, 2022. In order to determine the fair value of the acquired technology, customer relationships, tradename, and non-compete definite-lived intangible assets acquired from Global Cooling, the Company utilized the excess earnings approach, distributor method, relief from royalty method, and with and without approach, respectively. The key assumptions associated with determining the estimated fair value include (i) the amount and timing of projected future cash flows (including revenue and expenses), (ii) the discount rate selected to measure the risks inherent in the future cash flows, (iii) the assessment of the asset’s life cycle, and (iv) the competitive trends impacting the asset. These assumptions differed from those incorporated into the forecasts during impairment testing as of June 30, 2022 fourth December 31, 2022 Intangible asset impairment charges Fair value determinations require considerable judgment and are sensitive to changes in underlying assumptions, estimates and market factors. Estimating the fair value of the Company’s reporting unit, indefinite-lived intangible assets, and definite-lived intangible assets requires us to make assumptions and estimates regarding our future plans, as well as industry, economic, and regulatory conditions. These assumptions and estimates include projected future revenue growth rates, EBITDA margins, terminal growth rates, discount rates, royalty rates and other market factors. If current expectations of future growth rates, margins and cash flows are not June 30, 2022 October 1, 2022

Note 12 - Commitments and Conti

Note 12 - Commitments and Contingencies	12 Months Ended
Note 12 - Commitments and Contingencies	Dec. 31, 2022
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	12. Commitments and contingencies Employment agreements We have employment agreements with certain key employees. None may Litigation From time to time, the Company is subject to various legal proceedings that arise in the ordinary course of business, none may not Indemnification As permitted under Delaware law and in accordance with the Company’s bylaws, the Company is required to indemnify its officers and directors for certain errors and occurrences while the officer or director is or was serving in such capacity. The Company is also party to indemnification agreements with its directors. The Company believes the fair value of the indemnification rights and agreements is minimal. Accordingly, the Company has not December 31, 2022. Non-income related taxes Companies are required to collect and remit sales tax from certain customers if the company is determined to have nexus in a particular state. Upon the determination of nexus, which varies by state, companies are additionally required to maintain detailed record of specific product and customer information within each jurisdiction in which it has established nexus to appropriately determine their sales tax liability, requiring technical knowledge of each jurisdiction’s tax case law. During the year ended December 31, 2022, 2019 2022 2019 2022,

Note 13 - Line of Credit and Lo

Note 13 - Line of Credit and Long-term Debt	12 Months Ended
Note 13 - Line of Credit and Long-term Debt	Dec. 31, 2022
Notes to Financial Statements
Long-Term Debt [Text Block]	13. Line of credit and long-term debt Line of credit In May 2021, 3 October 2021, Long-term debt In May 2021, three 3 In October 2021, three one two one three one September 20, 2022, one three On September 20, 2022, June 1, 2026. June 30, 2023, June 2024, June 2025. 2022 3 2022 3 Long-term debt consisted of the following as of December 31, 2022 2021: December 31, (In thousands) Maturity Date Interest Rate 2022 2021 2022 term loan 1 ⁽¹⁾ 4.0 % $ - $ 1,750 2022 term loan 2 Various 4.0 % 2,896 2,813 2022 term loan 3 Jun-26 6.8 % 20,000 - Insurance premium financing Apr-23 5.0 % 1,074 373 Freezer equipment loan Dec-25 5.7 % 466 612 Manufacturing equipment loans Oct-25 5.7 % 266 355 Freezer installation loan Various 6.3 % 1,078 1,334 Other loans Various Various 6 9 Total debt, excluding unamortized debt issuance costs 25,786 7,246 Less: unamortized debt issuance costs (179 ) (31 ) Total debt 25,607 7,215 Less: current portion of debt (1,814 ) (862 ) Total long-term debt $ 23,793 $ 6,353 ( 1 2022 1 September 2024 December 31, 2021. September 20, 2022, 2022 3 2022 2 2022 3. As of December 31, 2022, five (In thousands) Amount 2023 $ 1,881 2024 5,544 2025 10,543 2026 5,221 2027 2,597 Thereafter - Total $ 25,786

Note 14 - Warrants

Note 14 - Warrants	12 Months Ended
Note 14 - Warrants	Dec. 31, 2022
Notes to Financial Statements
Warrants [Text Block]	14. Warrants In May 2020, Taurus4757 In March 2021, The following table summarizes warrant activity for the years ended December 31, 2021 2020: 2021 2020 Shares Wtd. Avg. Exercise Price Shares Wtd. Avg. Exercise Price Outstanding at beginning of year 79,100 $ 4.75 3,959,005 $ 4.33 Exercised (79,100 ) 4.75 (3,879,905 ) 4.33 Outstanding and exercisable at end of year - $ - 79,100 $ 4.75 There was no December 31, 2022.

Note 15 - Stock-based Compensat

Note 15 - Stock-based Compensation	12 Months Ended
Note 15 - Stock-based Compensation	Dec. 31, 2022
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	15. Stock-based compensation Stock compensation plans Our stock-based compensation programs are long-term retention programs that are intended to attract, retain, and provide incentives for talented employees, officers, and directors, and to align stockholder and employee interests. We have the following stock-based compensation plans and programs: During 2013, 2013 “2013 2013 May 2017, July 2020, June 2021, June 2022, December 31, 2022, 2013 Issuance of shares When options and warrants are exercised, it is the Company’s policy to issue new shares. Stock option activity Service vesting-based stock options The following is a summary of service vesting-based stock option activity for the year ended December 31, 2022 2021, December 31, 2022 2021: 2022 2021 Shares Wtd. Avg. Exercise Price Shares Wtd. Avg. Exercise Price Outstanding as of beginning of year 624,531 $ 2.13 844,455 $ 2.00 Exercised (161,646 ) 2.00 (183,064 ) 1.61 Forfeited - - (1,146 ) 5.69 Expired (6,592 ) 3.22 (35,714 ) 1.73 Outstanding at end of year 456,293 $ 2.17 624,531 $ 2.13 Stock options exercisable at year end 456,293 $ 2.17 624,531 $ 2.13 We recognized stock compensation expense related to service-based options of zero December 31, 2022, 2021, 2020. December 31, 2022, December 31, 2022. December 31, 2022, 2021, 2020 December 31, 2022, 2021, 2020. December 31, 2022 December 31, 2022. The following table summarizes information about service vesting-based stock options outstanding as of December 31, 2022: Range of Exercise Prices Number Outstanding at December 31, 2022 Weighted Average Remaining Contractual Life Weighted Average Exercise Price $1.00 - 1.50 2,000 3.85 $ 1.49 $1.51 - 2.00 177,500 3.28 1.90 $2.01 - 2.50 255,938 2.35 2.06 $2.51 - 8.60 20,855 4.92 5.69 456,293 2.84 $ 2.16 Performance-based stock options The Company’s Board of Directors implemented a Management Performance Bonus Plan for 2017. December 31, 2017, 2017 not no February 27, 2018, 2017 2018. The following is a summary of performance-based stock option activity under our stock option plans for the years ended December 31, 2021 December 31, 2021: 2021 Shares Wtd. Avg. Exercise Price Outstanding as of beginning of year 686,001 $ 1.64 Exercised (686,001 ) 1.64 Outstanding at end of year - $ 1.64 Stock options exercisable at year end - $ - There was no performance-based stock option grant activity during the year ended December 31, 2022. No stock compensation expense was recognized during the years ended December 31, 2022, 2021, 2020 December 31, 2022, 2021, 2020 zero December 31, 2022, 2021, 2020. Restricted stock Service vesting-based restricted stock The following is a summary of service vesting-based restricted stock activity for the years ended December 31, 2022 2021, December 31, 2022 2021: 2022 2021 Shares Wtd. Avg. Grant Date Fair Value Shares Wtd. Avg. Grant Date Fair Value Outstanding as of beginning of year 1,212,783 $ 37.48 930,854 $ 19.31 Granted 1,373,909 25.26 801,484 47.20 Vested (569,535 ) 35.51 (378,502 ) 19.31 Forfeited (137,942 ) 40.19 (141,053 ) 36.95 Non-vested at year end 1,879,215 $ 28.94 1,212,783 $ 37.48 On November 4, 2021, one 2023. four December 31, 2022. December 31, 2021 The aggregate fair value of the service vesting-based awards granted during the years ended December 31, 2022, 2021, 2020 December 31, 2022, 2021, 2020 During the months of May August 2022, December 31, 2022. Equity Incentive Compensation We recognized stock compensation expense of $21.0 million, $12.7 million, and $3.0 million related to service vesting-based awards during the years ended December 31, 2022, 2021, 2020, December 31, 2022, Performance-based restricted stock On March 25, 2020, 2020 December 31, 2020. We recognized stock compensation expense of zero zero December 31, 2022, 2021, 2020, December 31, 2022, The aggregate fair value of the performance-based awards granted during the years ended December 31, 2022, 2021, 2020 zero December 31, 2022, 2021, 2020 zero zero Market-based restricted stock The following is a summary of market-based restricted stock activity under our stock option plan for the years ended December 31, 2022 2021 December 31, 2022 2021: 2022 2021 Shares Wtd. Avg. Grant Date Fair Value Shares Wtd. Avg. Grant Date Fair Value Outstanding as of beginning of year 139,756 $ 19.86 224,774 $ 19.20 Granted 349,568 22.66 152,665 32.50 Vested (218,280 ) 10.95 (231,268 ) 26.98 Forfeited - - (6,415 ) 40.65 Non-vested at year end 271,044 $ 30.64 139,756 $ 19.86 On February 25, 2019 April 1, 2019 February 8, 2021, January 1, 2019 December 31, 2020 20 2 0% December 31, 2020. On March 25, 2020, February 24, 2022, January 1, 2020 December 31, 2022 20 January 1, 2020 December 31, 2021 20 0% 2 December 31, 2021. On February 8, 2021, January 1, 2021 December 31, 2022 20 0% December 31, 2022. On May 3, 2021, one January 1, 2021 December 31, 2022 20 0% November 2021, December 31, 2021 On February 24, 2022, January 1, 2022 December 31, 2023 20 0% December 31, 2023. We recognized stock compensation expense of $4.3 million, $1.4 million, and $2.1 million related to market-based restricted stock awards for the years ended December 31, 2022, 2021, 2020. December 31, 2022, The aggregate fair value of the market-based awards granted during the years ended December 31, 2022, 2021, 2020 December 31, 2022, 2021, 2020 Total stock compensation expense We recorded total stock compensation expense for the years ended December 31, 2022, 2021, 2020, 2022 2021 2020 Research and development costs $ 3,176 $ 1,906 $ 1,012 Sales and marketing costs 3,649 1,788 852 General and administrative costs 14,066 8,061 3,518 Cost of revenue 4,443 2,201 599 Total $ 25,334 $ 13,956 $ 5,981

Note 16 - Income Taxes

Note 16 - Income Taxes	12 Months Ended
Note 16 - Income Taxes	Dec. 31, 2022
Notes to Financial Statements
Income Tax Disclosure [Text Block]	16. Income taxes The following are the domestic and foreign components of the Company's loss before income taxes: Year Ended December 31, (In thousands) 2022 2021 2020 Domestic $ (146,091 ) $ (28,590 ) $ (1,281 ) Foreign 1,264 (436 ) - Total $ (144,827 ) $ (29,026 ) $ (1,281 ) Income tax benefit consists of the following: Year Ended December 31, (In thousands) 2022 2021 2020 Current: Federal $ - $ - $ - State 11 - 33 Foreign 205 9 - Total current tax provision 216 9 33 Deferred: Federal (2,924 ) (17,703 ) (3,297 ) State (2,314 ) (2,424 ) - Foreign - - - Total deferred tax benefit (5,238 ) (20,127 ) (3,297 ) Income tax benefit $ (5,022 ) $ (20,118 ) $ (3,264 ) In the years ended December 31, 2021 2020, December 31, 2022 not In connection with the 2021 2021 In connection with the 2020 A reconciliation of income taxes computed using the U.S. federal statutory rate to that reflected in operations follows: Year Ended December 31, 2022 2021 2020 Federal statutory tax 21 % 21 % 21 % State tax, net of federal benefit 3 % 7 % 20 % Stock compensation - 36 % 251 % Sec. 162(m) limitation on executive compensation (1 %) (11 %) (16 %) Fair value change in contingent consideration 1 % (2 %) (38 %) Fair value change in warrant liability - - 59 % Transaction costs - (1 %) (3 %) Gain on stock acquisition - 5 % - Tax credits 1 % - 6 % Change in valuation allowance (21 %) 20 % 4 % Expired net operating losses - (5 %) (47 %) Other - (1 %) (2 %) Total 4 % 69 % 255 % The principal components of the Company’s net deferred tax assets are as follows as of December 31, 2022 2021: (In thousands) 2022 2021 Deferred tax assets related to: Net operating loss carryforwards $ 29,102 $ 27,500 Stock-based compensation 3,207 2,066 Accruals and reserves 3,724 3,402 Inventory 425 236 Lease liabilities 3,653 4,198 Tax credit carryforward 1,423 594 Capitalized research and development 2,405 - Other 445 318 Total deferred tax assets 44,384 38,314 Deferred tax liabilities related to: Intangibles (6,150 ) (35,241 ) Right-of-use assets (3,458 ) (4,070 ) Fair value change in investments (447 ) (294 ) Fixed assets (1,177 ) (1,203 ) Other - - Total deferred tax liabilities (11,232 ) (40,808 ) Net deferred tax (liabilities) assets before valuation allowance 33,152 (2,494 ) Less: valuation allowance (33,402 ) (2,993 ) Net deferred tax liabilities $ (250 ) $ (5,487 ) Realization of deferred tax assets is dependent upon the generation of future taxable income, if any, the timing and amount of which are uncertain. The assessment regarding whether a valuation allowance is required on deferred tax assets considers the evaluation of both positive and negative evidence when concluding whether it is more likely than not December 31, 2022 2021 The changes in the valuation allowance for deferred tax assets were as follows: (In thousands) 2022 2021 2020 Balance at January 1 $ 2,993 $ 8,498 $ 8,706 Deferred tax liabilities assumed through acquisitions - (8,498 ) (3,297 ) Charged to income tax expense 30,409 2,993 3,089 Balance at December 31 $ 33,402 $ 2,993 $ 8,498 As of December 31, 2022, 2023 2037, may may The Tax Cuts and Jobs Act contained a provision which requires the capitalization of Section 174 January 1, 2022. 174 174 no December 31, 2022. The Company determines its uncertain tax positions based on a determination of whether and how much of a tax benefit taken by the Company in its tax filings or positions is more likely than not A reconciliation of the beginning and ending balances of uncertain tax positions in the years ended December 31, 2022 2021 (In thousands) 2022 2021 Balance at January 1 $ 255 $ 96 Increase related to prior year tax positions 170 - Increase related to current year tax positions 185 159 Balance at December 31 $ 610 $ 255 The Company is generally subject to examination by U.S. federal and local income tax authorities for all tax years in which loss carryforward is available, which includes 2003 2022.

Note 17 - Acquisitions

Note 17 - Acquisitions	12 Months Ended
Note 17 - Acquisitions	Dec. 31, 2022
Notes to Financial Statements
Business Combination Disclosure [Text Block]	17. Acquisitions Sexton acquisition General terms and effects On August 9, 2021, On September 1, 2021, December 31, 2021. Total consideration transferred (in thousands, except number of shares and stock price): Merger consideration shares 530,502 BioLife stock price (as of September 1, 2021) $ 60.50 Value of issued shares $ 32,095 plus: Fair value of BioLife’s existing investment in Sexton $ 7,951 less: Net working capital adjustment $ (118 ) Merger Consideration $ 39,928 Transaction costs related to the acquisition are expensed as incurred and are not Fair value of net assets acquired Under the acquisition method of accounting, the assets acquired and liabilities assumed from Sexton were calculated as of the merger date, at their respective fair values, and consolidated with those of BioLife. The gross contractual accounts receivable acquired in the acquisition was $509,000. Of the acquired accounts receivable, $17,000 is estimated to be uncollectable. The fair value calculations required critical estimates, including, but not The table below represents the fair value of the net assets acquired and liabilities assumed, which were recorded as of the merger date (amounts in thousands). Cash $ 1,516 Accounts receivable, net 492 Inventory 1,310 Prepaid expenses and other current assets 670 Property, plant and equipment, net 737 Operating lease right-of-use assets, net 470 Developed technology 4,132 Customer relationships 2,276 Tradenames 2,324 Non-compete agreements 90 Goodwill 28,470 Accounts payable (291 ) Lease liabilities, operating (470 ) Deferred tax liability (1,482 ) Other liabilities (316 ) Fair value of net assets acquired $ 39,928 We recorded a measurement period adjustment in the fourth December 31, 2021 The fair value of Sexton’s identifiable intangible assets and useful lives are as follows (amounts in thousands, except years): Fair Value Useful Life (Years) Developed technology $ 4,132 5 - 9 Customer relationships 2,276 2 Tradenames 2,324 11 Non-compete agreements 90 1 Total identifiable intangible assets $ 8,822 Fair value measurement methodologies used to calculate the value of any asset can be broadly classified into one three three not Some of the more significant assumptions inherent in the development of intangible asset fair values, from the perspective of a market participant, include, but are not Acquired goodwill The goodwill of $28.5 million represents future economic benefits expected to arise from synergies from combining operations and commercial organizations to increase market presence and the extension of existing customer relationships. The goodwill recorded is not Global Cooling acquisition General terms and effects On March 19, 2021, On May 3, 2021, Merger consideration The aggregate merger consideration paid pursuant to the GCI Merger Agreement to the GCI Stockholders was 6,646,870 newly issued shares of common stock, provided, however, that the GCI Merger Consideration otherwise payable to GCI Stockholders is subject to the withholding of the GCI Escrow Shares (as defined below) and is subject to reduction for indemnification obligations. The GCI Merger Consideration allocable to one 805, not Total consideration transferred (in thousands, except number of shares, stock price, and consideration percentage): BioLife shares outstanding (as of March 19, 2021) 33,401,359 Merger consideration percentage 19.9 % Merger consideration shares 6,646,870 less: Merger consideration shares withheld to satisfy outstanding GCI stockholder obligations to GCI 10,400 Subtotal 6,636,470 BioLife stock price (as of May 3, 2021) $ 35.07 Value of issued shares $ 232,741 plus: Settlement of BioLife prepaid deposits $ 2,152 plus: Net settlement of BioLife accounts receivable $ 16 Merger Consideration $ 234,909 Transaction costs related to the acquisition are expensed as incurred and are not Escrow shares At the GCI Closing, approximately nine The GCI Escrow Property will be held for a period of up to twenty-four Fair value of net assets acquired Under the acquisition method of accounting, the assets acquired and liabilities assumed from Global Cooling were calculated as of the merger date, at their respective fair values, and consolidated with those of BioLife. The gross contractual accounts receivable acquired in the acquisition was $7.1 million. Of the acquired accounts receivable, $53,000 was estimated to be uncollectable. The fair value calculations required critical estimates, including, but not The table below represents the fair value of the net assets acquired and liabilities assumed, which were recorded as of the merger date (amounts in thousands). Cash $ 43 Accounts receivable, net 7,076 Inventory 15,547 Prepaid expenses and other current assets 639 Property, plant and equipment, net 3,512 Operating lease right-of-use assets, net 1,741 Financing lease right-of-use assets, net 114 Long-term deposits and other assets 4 Developed technology 18,140 Customer relationships 7,020 Tradenames 26,640 Non-compete agreements 1,240 In-process research and development 67,440 Goodwill 137,822 Accounts payable (9,837 ) Line of credit (4,231 ) Lease liabilities, operating (1,880 ) Lease liabilities, financing (114 ) Long-term debt (4,410 ) Deferred tax liability (24,133 ) Other liabilities (7,464 ) Fair value of net assets acquired $ 234,909 We recorded a measurement period adjustment in the fourth December 31, 2021 The fair value of Global Cooling’s identifiable intangible assets and useful lives are as follows (amounts in thousands, except years): Fair Value Useful Life (Years) Developed technology $ 18,140 6 Customer relationships 7,020 12 Tradenames 26,640 15 Non-compete agreements 1,240 4 In-process research and development 67,440 N/A Total identifiable intangible assets $ 120,480 Fair value measurement methodologies used to calculate the value of any asset can be broadly classified into one three three not Some of the more significant assumptions inherent in the development of intangible asset fair values, from the perspective of a market participant, include, but are not Acquired goodwill The goodwill of $137.8 million represents future economic benefits expected to arise from synergies from combining operations and commercial organizations to increase market presence and the extension of existing customer relationships. The goodwill recorded is not SciSafe acquisition On September 18, 2020, one hundred October 1, 2020. Consideration transferred The SciSafe Acquisition was accounted for as a purchase of a business under FASB ASC Topic 805, Business Combinations 2021 2024. not Total consideration transferred (in thousands): Cash consideration $ 15,000 Stock consideration 17,916 Contingent consideration 3,663 Working capital adjustment (53 ) Total consideration transferred $ 36,526 Fair value of net assets acquired The table below represents the purchase price allocation to the net assets acquired based on their fair values (amounts in thousands). Cash $ 500 Accounts receivable, net 945 Prepaid expenses and other current assets 31 Property, plant and equipment, net 3,400 Customer relationships 7,420 Tradenames 4,020 Non-compete agreements 660 Goodwill 24,943 Other assets 1,547 Accounts payable (885 ) Deferred tax liability (3,297 ) Other liabilities (2,758 ) Fair value of net assets acquired $ 36,526 On September 30, 2020, The fair value of SciSafe’s identifiable intangible assets and useful lives are as follows (amounts in thousands except years): Fair Value Useful Life (Years) Customer relationships $ 7,420 14 Tradenames 4,020 19 Non-compete agreements 660 4 Total identifiable intangible assets $ 12,100 Fair value measurement methodologies used to calculate the value of any asset can be broadly classified into one three three not Some of the more significant assumptions inherent in the development of intangible asset fair values, from the perspective of a market participant, include, but are not Indemnification asset In 2020, 805. Acquired goodwill The goodwill of $24.9 million represents future economic benefits expected to arise from synergies from combining operations and commercial organizations to increase market presence and the extension of existing customer relationships. The goodwill recorded is not Fair value measurement methodologies used to calculate the value of any asset can be broadly classified into one three three third Some of the more significant assumptions inherent in the development of intangible asset fair values, from the perspective of a market participant, include, but are not not Revenue, net income, and pro forma presentation The Company recorded revenue from Sexton of $1.8 million and a net loss of $1.0 million from September 1, 2021, December 31, 2021. May 3, 2021, December 31, 2021. October 1, 2020, December 31, 2020. The following unaudited pro forma financial information presents the combined results of operations of Sexton as if the acquisition had occurred on January 1, 2020 2021 2020 (In thousands) (unaudited) (unaudited) Total revenue $ 122,494 $ 50,856 Net loss $ (9,860 ) $ (1,028 ) The following unaudited pro forma financial information presents the combined results of operations of Global Cooling as if the acquisition had occurred on January 1, 2020 2021 2020 (In thousands) (unaudited) (unaudited) Total revenue $ 143,732 $ 87,370 Net income (loss) $ (16,375 ) $ 501 The following unaudited pro forma financial information presents the combined results of operations of SciSafe as if the acquisition had occurred on January 1, 2020 2020 (In thousands) (unaudited) Total revenue $ 52,613 Net income $ 1,798

Note 18 - Employee Benefit Plan

Note 18 - Employee Benefit Plan	12 Months Ended
Note 18 - Employee Benefit Plan	Dec. 31, 2022
Notes to Financial Statements
Defined Contribution Plan [Text Block]	18. Employee benefit plan The Company sponsors 401 may December 31, 2022, 2021, 2020.

Note 19 - Selected Quarterly Da

Note 19 - Selected Quarterly Data	12 Months Ended
Note 19 - Selected Quarterly Data	Dec. 31, 2022
Notes to Financial Statements
Quarterly Financial Information [Text Block]	19. Subsequent events The Company has evaluated events subsequent to December 31, 2022 no

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
Significant Accounting Policies (Policies)	Dec. 31, 2022
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of estimates The preparation of financial statements in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions by management affect the Company’s allowance for doubtful accounts, the net realizable value of inventory, fair value of warrant liability, sales tax liabilities, valuation of market based awards, valuations and purchase price allocations related to investments and business combinations, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, amortization methods and periods, warranty reserves, certain accrued expenses, share-based compensation, contingent consideration from business combinations, and the provision for income taxes. The Company regularly assesses these estimates; however, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances.
Basis of Accounting, Policy [Policy Text Block]	Basis of presentation The Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries, SAVSU Technologies, Inc. (“SAVSU”), Arctic Solutions, Inc. doing business as CBS, SciSafe (acquired on October 1, 2020), May 3, 2021), September 1, 2021). All long-lived assets are maintained in the United States of America and the Netherlands.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign currency translation The Company translates balance sheet and income statement items into U.S. dollars. For the Company’s subsidiaries that operate in a local currency functional environment, all assets and liabilities are translated into U.S. dollars using current exchange rates at the balance sheet date; revenue and expenses are translated using quarterly exchange rates which approximate to average exchange rates in effect during each period. Resulting translation adjustments are reported as a separate component of accumulated other comprehensive (loss) income in shareholders' equity.
Segment Reporting, Policy [Policy Text Block]	Segment reporting The Company views its operations and makes decisions regarding how to allocate resources and manages its business as one one
Revenue [Policy Text Block]	Revenue recognition To determine revenue recognition for contractual arrangements that we determine are within the scope of Financial Accounting Standards Board (“FASB”) Topic 606, Revenue from Contracts with Customers five five may not 30 90 December 31, 2022, The Company primarily recognizes product revenues, service revenues, and rental revenues. Product revenues are generated from the sale of biopreservation media, ThawSTAR, and freezer products. We recognize product revenue, including shipping and handling charges billed to customers, at a point in time when we transfer control of our products to our customers, which is upon shipment for substantially all transactions. Shipping and handling costs are classified as part of cost of product revenue in the Consolidated Statement of Operations. Service revenues are generated from the storage of biological and pharmaceutical materials. We recognize service revenues over time as services are performed or ratably over the contract term. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount method, depending on the facts and circumstances relative to the contract. When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in paragraph 606 10 32 18, not one None December 31, 2022. The Company also generates revenue from the leasing of our property, plant, and equipment, operating right-of-use assets, and evo cold chain systems to customers pursuant to service contracts or rental arrangements entered into with the customer. Revenue from these arrangements is not 606 842, Lease The Company enters into various customer service agreements (collectively, “Service Contracts”) with customers to provide biological and pharmaceutical storage services. In certain of these Service Contracts, the property, plant, and equipment or operating right-of-use assets used to store a customer’s product are used only for the benefit of one may not The Company has assessed its Service Contracts and concluded that certain of the contracts for the storage of customer products met the criteria to be considered a leasing arrangement (“Embedded Leases”), with the Company as the lessor. The specific Service Contracts that met the criteria were those that provided a single customer with the ability to substantially direct the use of the Company’s property, plant, and equipment or operating right-of-use assets. Under ASC 842, None None Embedded Leases may Total bioproduction tools and services revenue for the years ended December 31, 2022, 2021, 2020 Year Ended December 31, (In thousands, except percentages) 2022 2021 2020 Product revenue Freezer and thaw $ 66,682 $ 56,620 $ 13,548 Cell processing 68,509 44,965 30,946 Storage and cold chain services 809 328 46 Service revenue Freezer and thaw 74 - - Storage and cold chain services 15,234 9,817 1,752 Rental revenue Storage and cold chain services 10,451 7,426 1,795 Total revenue $ 161,759 $ 119,156 $ 48,087 ( 1 2021 May 3, 2021 December 31, 2021 September 1, 2021 December 31, 2021. ( 2 2020 October 1, 2020 December 31, 2020. The following table includes estimated rental revenue expected to be recognized in the future related to embedded leases as well as estimated service revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting periods. The Company elected not one 2014 09, Revenue from Contracts with Customers not one December 31, 2022. The balances in the table below are partially based on judgments involved in estimating future orders from customers subject to the exercise of material rights pursuant to respective contracts: (In thousands) 2023 2024 Total Rental revenue $ 3,735 $ 900 $ 4,635 Service revenue $ 200 $ 10 $ 210
Risk and Uncertainties, Policy [Policy Text Block]	Risks and uncertainties COVID- 19 Our domestic and international operations have been and continue to be affected by the ongoing global pandemic of a novel strain of coronavirus (“COVID- 19” During year ended December 31, 2021, 19. December 31, 2022, December 31, 2021. December 31, 2022. We cannot be assured that a continued or prolonged global pandemic will not 19 19. The Company reviews capital and amortizing intangible assets (long-lived assets) for impairment on an annual basis or whenever events or changes in circumstances indicate that the carrying amount may not 19 June 30, 2020 19. As a result of the Company’s outlook for revenue from the ThawSTAR and freezer product lines, estimated undiscounted cash flow projections were developed to determine if any impairment of the related intangible assets was warranted. After conducting such review, the Company determined that there was no June 30, 2020. 19 The Company revised the revenue projections for the ThawSTAR and freezer product lines in the second June 30, 2020 December 31, 2020 two no December 31, 2020. June 30, 2020, December 31, 2020 December 31, 2020. The Company may 19 third Any disruption and volatility in the global capital markets as a result of the pandemic may 19 not The ultimate extent to which the COVID- 19 19 On April 20, 2020, April 29, 2020.
Earnings Per Share, Policy [Policy Text Block]	Earnings per share The Company considers its unexercised warrants and unvested restricted shares, which contain non-forfeitable rights to dividends, participating securities, and includes such participating securities in its computation of earnings per share pursuant to the two two two The following table presents computations of basic and diluted earnings per share under the two Year Ended December 31, (In thousands, except share and earnings per share data) 2022 2021 2020 Basic earnings (loss) per common share Numerator: Net (loss) income $ (139,805 ) $ (8,908 ) $ 1,983 Amount attributable to unvested restricted shares - - (100 ) Amount attributable to warrants outstanding - - (61 ) Net (loss) income allocated to common shareholders (139,805 ) (8,908 ) 1,822 Denominator: Weighted-average common shares issued and outstanding 42,481,027 38,503,944 27,306,258 Basic (loss) earnings per common share $ (3.29 ) $ (0.23 ) $ 0.07 Diluted earnings (loss) per common share Numerator: Net (loss) income $ (139,805 ) $ (8,908 ) $ 1,983 Amount attributable to warrants - - (14 ) Less: gain related to change in fair value of warrants - - (3,601 ) Net loss allocated to common shareholders (139,805 ) (8,908 ) (1,632 ) Denominator: Weighted-average common shares issued and outstanding 42,481,027 38,503,944 27,306,258 Diluted loss per common share $ (3.29 ) $ (0.23 ) $ (0.06 ) The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive: Year Ended December 31, 2021 2020 Stock options and restricted stock awards 1,637,745 2,131,794 Warrants 18,204 1,499,953 Total 1,655,949 3,631,747
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash, cash equivalents, and restricted cash Cash equivalents consist primarily of interest-bearing money market accounts. We consider all highly liquid debt instruments purchased with an initial maturity of three may not Restricted cash consists entirely of amounts that will be recovered from escrow in relation to the acquisition of SciSafe. The restricted cash is short term in nature, as the Company anticipates to receive the funds within one The following is a summary of the Company’s cash, cash equivalents, and restricted cash total as presented in the Company’s Consolidated Statements of Cash Flows for the years ended December 31, 2022 2021. (In thousands) 2022 2021 Cash and cash equivalents $ 19,442 $ 69,860 Restricted cash 31 10 Total cash, cash equivalents, and restricted cash $ 19,473 $ 69,870
Marketable Securities, Policy [Policy Text Block]	Available-for-sale securities Available-for-sale securities consist of U.S. government securities, corporate debt securities, and other debt securities. Management classifies investments at the time of purchase and reevaluates such classification at each balance sheet date. Investments with maturities beyond one may
Inventory, Policy [Policy Text Block]	Inventories Inventories relate to the Company’s cell and gene therapy products. The Company values biopreservation media inventory at cost or, if lower, net realizable value, using the specific identification method. All other inventory is valued at cost or, if lower, net realizable value, using the first first no
Accounts Receivable [Policy Text Block]	Accounts receivable Accounts receivable consist of short-term amounts due from our customers (generally 30 90 Accounts receivable are stated at principal amount, do not
Investment, Policy [Policy Text Block]	Equity investments We periodically invest in securities of private companies to promote business and strategic objectives. These investments are measured and recorded as follows: Non-marketable equity securities are equity securities without a readily determinable fair value. As of December 31, 2022, 1 2 December 31, 2021, 1 2 As of December 31, 2022, September 1, 2021. December 31, 2020, not zero December 31, 2022, 2021, 2020, November 2020, 1 2 In November 2020, June 2021, first As of December 31, 2022, no
Property, Plant and Equipment, Policy [Policy Text Block]	Property and equipment Property and equipment are stated at cost and are depreciated using the straight-line method over estimated useful lives of three ten Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that their net book value may not may no December 31, 2022, 2021, 2020.
Assets Held for Rent, Policy [Policy Text Block]	Assets held for rent Assets held for rent are carried at cost less accumulated depreciation. These assets consist of dedicated storage space, evo shippers and related components in production shippers complete and ready to be deployed and placed in service upon a customer order, shippers in the process of being assembled, and components available to build shippers. Assets utilized to provide dedicated storage space are depreciated over their applicable useful lives once placed in service. Shippers are depreciated over a useful life of three Our customers rent assets per a rental agreement. Each agreement provides for fixed monthly rent. Rental revenue and fees are recognized over the rental term on a straight-line basis. We retain the ownership of the assets rented. At the end of the rental agreement, the customer returns the asset to the Company. Assets held for rent are reviewed for impairment whenever events or changes in circumstances indicate that their net book value may not may December 31, 2022, 2021, 2020.
Lessee, Leases [Policy Text Block]	Lease accounting We determine if an arrangement is a lease at inception. Where an arrangement is a lease, we determine if it is an operating lease or a financing lease. At lease commencement, we record a lease liability and corresponding right-of-use (“ROU”) asset. Lease liabilities represent the present value of our future lease payments over the expected lease term which includes options to extend or terminate the lease when it is reasonably certain those options will be exercised. The present value of our lease liability is determined using our incremental collateralized borrowing rate at lease inception. ROU assets represent our right to control the use of the leased asset during the lease and are recognized in an amount equal to the lease liability for leases with an initial term greater than 12 We elected to apply the practical expedient for short-term leases and accordingly do not twelve
Standard Product Warranty, Policy [Policy Text Block]	Warranty Our standard warranty terms typically extend between one seven
Income Tax, Policy [Policy Text Block]	Income taxes We account for income taxes using an asset and liability method which generally requires recognition of deferred tax assets and liabilities for the expected future tax effects of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are recognized for the future tax effects of differences between tax bases of assets and liabilities, and financial reporting amounts, based upon enacted tax laws and statutory rates applicable to the periods in which the differences are expected to affect taxable income. We evaluate the likelihood of realization of deferred tax assets and provide an allowance where, in management’s opinion, it is more likely than not not We determine any uncertain tax positions based on a determination of whether and how much of a tax benefit taken in the Company’s tax filings or positions is more likely than not Judgment is applied in the determination of the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. As of December 31, 2022,
Advertising Cost [Policy Text Block]	Advertising Advertising costs are expensed as incurred and totaled $768,000, $552,000, and $167,000 for the years ended December 31, 2022, 2021, 2020,
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of risk During the years ended December 31, 2022 2021, December 31, 2020, No 10% Year Ended December 31, Revenue by major product 2022 2021 2020 CryoStor 36 % 33 % 60 % 780XLE Freezer 22 % 22 % - % In the years ended December 31, 2022, 2021, 2020, no 10% The following table represents the Company’s total revenue by geographic area (based on the location of the customer): Year Ended December 31, Revenue by customers geographic locations 2022 2021 2020 United States 72 % 78 % 73 % Canada 17 % 7 % 13 % Europe, Middle East, Africa (EMEA) 7 % 14 % 12 % Other 4 % 1 % 2 % Total revenue 100 % 100 % 100 % The following table represents the Company’s long-lived assets by geographic area as of December 31: (In thousands) 2022 2021 United States $ 42,829 $ 40,708 Netherlands 5,437 5,903 Total $ 48,266 $ 46,611 As of December 31, 2022, two December 31, 2021, two No 10% As of December 31, 2022, one December 31, 2021, No 10%
Research and Development Expense, Policy [Policy Text Block]	Research and development Research and development costs are expensed as incurred.
Share-Based Payment Arrangement [Policy Text Block]	Stock-based compensation We measure and record compensation expense using the applicable accounting guidance for share-based payments related to stock options, time-based restricted stock, market-based restricted stock awards and performance-based restricted stock awards granted to our directors and employees. The fair value of stock options, including performance awards, without a market-based condition is determined by using the Black-Scholes option-pricing model. The fair value of restricted stock awards with a market condition is estimated at the date of grant using the Monte Carlo Simulation model. The Black-Scholes and Monte Carlo Simulation valuation models incorporate assumptions as to stock price volatility, the expected life of options or awards, a risk-free interest rate and dividend yield. The fair value of restricted stock, including performance awards, without a market condition is estimated using the current market price of our common stock on the date of grant. We expense stock-based compensation for stock options, restricted stock awards, and performance awards over the requisite service period. For awards with only a service condition, we expense stock-based compensation using the straight-line method over the requisite service period for the entire award. For awards with a market condition, we expense the grant date fair value over the vesting period regardless of the value that the award recipients ultimately receive. We have, from time to time, modified the terms of restricted stock awards awarded to employees. We account for the incremental increase in the fair value over the original award on the date of the modification as an expense for vested awards or over the remaining service (vesting) period for unvested awards. The incremental compensation cost is the excess of the fair value of the modified award on the date of modification over the fair value of the original award immediately before the modification.
Business Combinations Policy [Policy Text Block]	Business combinations, goodwill, and intangible assets Business combinations The Company accounts for business acquisitions using the acquisition method as required by FASB ASC Topic 805, Business Combinations The Company’s identifiable assets acquired and liabilities, including identified intangible assets, assumed in a business combination are recorded at their acquisition date fair values. The valuation requires management to make significant estimates and assumptions, especially with respect to long-lived and intangible assets. Critical estimates in valuing intangible assets include, but are not ● future expected cash flows, including revenue and expense projections; ● discount rates to determine the present value of recognized assets and liabilities and; ● revenue volatility to determine contingent consideration using option pricing models Goodwill is calculated as the excess of the acquisition price over the fair value of net assets acquired, including the amount assigned to identifiable intangible assets. Acquisition-related costs, including advisory, legal, accounting, valuation, and other costs, are expensed in the periods in which these costs are incurred. The results of operations of an acquired business are included in the consolidated financial statements beginning at the acquisition date. The Company estimates the acquisition date fair value of the acquisition-related contingent consideration using various valuation approaches, including option pricing models, as well as significant unobservable inputs, reflecting the Company’s assessment of the assumptions market participants would use to value these liabilities. The fair value of the contingent consideration is remeasured each reporting period. During the measurement period, which may one
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill Goodwill represents the excess of the purchase price over the net amount of identifiable assets acquired and liabilities assumed in a business combination measured at fair value. Goodwill is not fourth may first not 350, Intangibles Goodwill and Other not 50 not not not not one fourth 2022. no
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Intangible assets Intangible assets with a definite life are amortized over their estimated useful lives using the straight-line method and the amortization expense is recorded within intangible asset amortization in the Consolidated Statements of Operations. If the estimate of a definite-lived intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset is amortized prospectively over the revised remaining useful life. Definite-lived intangible assets and their related estimated useful lives are reviewed at least annually to determine if any adverse conditions exist that would indicate the carrying value of these assets may not June 30, 2022 October 1, 2022, 11 Indefinite-lived intangibles are carried at the initially recorded fair value less any recognized impairment. In-process research and development (“IPR&D”) is initially capitalized at fair value as an intangible asset with an indefinite life. When the IPR&D project is complete, it is reclassified as a definite-lived intangible asset and is amortized over its estimated useful life. If an IPR&D project is abandoned, a charge would be recorded for the value of the related intangible asset to our Consolidated Statement of Operations in the period it is abandoned. Indefinite-lived intangibles are tested annually for impairment. Impairment assessments are conducted more frequently if certain conditions exist, including a change in the competitive landscape, any internal decisions to pursue new or different technology strategies, a loss of a significant customer, or a significant change in the marketplace, including changes in the prices paid for the Company’s products or changes in the size of the market for the Company’s products. If impairment indicators are present, the Company determines whether the underlying intangible asset is recoverable through estimated future undiscounted cash flows. If the asset is not second 2022, 2021. June 30, 2022 October 1, 2022, 11
Warrants, Policy [Policy Text Block]	Certain warrants which have features that may Warrants that include cash settlement features are recorded as liabilities at their estimated fair value at the date of issuance and are remeasured at fair value each reporting period with the increase or decrease in fair value recorded in the Consolidated Statements of Operations. The warrants are measured at estimated fair value using the Black Scholes valuation model, which is based, in part, upon inputs for which there is little or no zero December 31, 2022, no
New Accounting Pronouncements, Policy [Policy Text Block]	Recent accounting pronouncements In June 2022, No. 2022 03, Fair Value Measurements (Topic 820 820” 2022 03 1 820, 2 3 820. 2022 03 not not December 15, 2023, 2022 03. not In March 2022, No. 2022 02 Financial Instruments-Credit Losses (Topic 326 2022 02 2022 02 326 2022 02 December 15, 2022 not In November 2021, No. 2021 10, Government Assistance (Topic 832 December 15, 2023, In October 2021, No. 2021 08, Business Combinations (Topic 805 Accounting for Contract Assets and Contract Liabilities from Contracts with Customers Revenue from Contracts with Customers (Topic 606 606 2021 08 December 15, 2022, not In March 2020, No. 2020 04, Reference Rate Reform (Topic 848 2020 04 January 2021, 2021 01, Reference Rate Reform Scope December 2022, 2022 06, Reference Rate Reform Deferral of the Sunset Date of Topic 848 2020 04 December 31, 2024. not In June 2016, No. 2016 13, Financial Instruments Credit Losses (Topic 326 2016 13 November 19, 2019, 2016 13 December 15, 2023,

Note 1 - Organization and Sig_2

Note 1 - Organization and Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Revenues By Product Line [Table Text Block]	Year Ended December 31, (In thousands, except percentages) 2022 2021 2020 Product revenue Freezer and thaw $ 66,682 $ 56,620 $ 13,548 Cell processing 68,509 44,965 30,946 Storage and cold chain services 809 328 46 Service revenue Freezer and thaw 74 - - Storage and cold chain services 15,234 9,817 1,752 Rental revenue Storage and cold chain services 10,451 7,426 1,795 Total revenue $ 161,759 $ 119,156 $ 48,087
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]	(In thousands) 2023 2024 Total Rental revenue $ 3,735 $ 900 $ 4,635 Service revenue $ 200 $ 10 $ 210
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Year Ended December 31, (In thousands, except share and earnings per share data) 2022 2021 2020 Basic earnings (loss) per common share Numerator: Net (loss) income $ (139,805 ) $ (8,908 ) $ 1,983 Amount attributable to unvested restricted shares - - (100 ) Amount attributable to warrants outstanding - - (61 ) Net (loss) income allocated to common shareholders (139,805 ) (8,908 ) 1,822 Denominator: Weighted-average common shares issued and outstanding 42,481,027 38,503,944 27,306,258 Basic (loss) earnings per common share $ (3.29 ) $ (0.23 ) $ 0.07 Diluted earnings (loss) per common share Numerator: Net (loss) income $ (139,805 ) $ (8,908 ) $ 1,983 Amount attributable to warrants - - (14 ) Less: gain related to change in fair value of warrants - - (3,601 ) Net loss allocated to common shareholders (139,805 ) (8,908 ) (1,632 ) Denominator: Weighted-average common shares issued and outstanding 42,481,027 38,503,944 27,306,258 Diluted loss per common share $ (3.29 ) $ (0.23 ) $ (0.06 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Year Ended December 31, 2021 2020 Stock options and restricted stock awards 1,637,745 2,131,794 Warrants 18,204 1,499,953 Total 1,655,949 3,631,747
Schedule of Cash and Cash Equivalents [Table Text Block]	(In thousands) 2022 2021 Cash and cash equivalents $ 19,442 $ 69,860 Restricted cash 31 10 Total cash, cash equivalents, and restricted cash $ 19,473 $ 69,870
Revenue from External Customers by Products and Services [Table Text Block]	Year Ended December 31, Revenue by major product 2022 2021 2020 CryoStor 36 % 33 % 60 % 780XLE Freezer 22 % 22 % - % Year Ended December 31, Revenue by customers geographic locations 2022 2021 2020 United States 72 % 78 % 73 % Canada 17 % 7 % 13 % Europe, Middle East, Africa (EMEA) 7 % 14 % 12 % Other 4 % 1 % 2 % Total revenue 100 % 100 % 100 % (In thousands) 2022 2021 United States $ 42,829 $ 40,708 Netherlands 5,437 5,903 Total $ 48,266 $ 46,611

Note 2 - Revision of Previous_2

Note 2 - Revision of Previously Issued Consolidated Financial Statements (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]	December 31, 2021 As reported Adjustment As corrected Prepaid expenses and other current assets $ 4,427 $ 229 $ 4,656 Total current assets 125,859 229 126,088 Total assets 554,057 229 554,286 Accrued expenses and other current liabilities (1) 7,142 (272 ) 6,870 Sales taxes payable - 2,591 2,591 Total current liabilities 40,381 2,319 42,700 Total liabilities 73,920 2,319 76,239 Accumulated deficit (2) (105,020 ) (2,090 ) (107,110 ) Total shareholders’ equity 480,137 (2,090 ) 478,047 Total liabilities and shareholders’ equity 554,057 229 554,286 Years Ended December 31, 2021 and 2020 2021 As reported Adjustment As corrected General and administrative $ 32,448 $ 1,220 $ 33,668 Total operating expenses 153,096 1,220 154,316 Operating loss (33,940 ) (1,220 ) (35,160 ) Interest expense (432 ) (53 ) (485 ) Total other income, net 6,187 (53 ) 6,134 Loss before income tax benefit (27,753 ) (1,273 ) (29,026 ) Net loss (1) (7,635 ) (1,273 ) (8,908 ) Net loss per basic share (0.20 ) (0.03 ) (0.23 ) Net loss per diluted share (0.20 ) (0.03 ) (0.23 ) 2020 General and administrative 14,607 666 15,273 Total operating expenses 53,662 666 54,328 Operating loss (5,575 ) (666 ) (6,241 ) Interest income 58 (18 ) 40 Total other income, net 4,978 (18 ) 4,960 Loss before income tax benefit (597 ) (684 ) (1,281 ) Net income (1) 2,667 (684 ) 1,983 Net income attributable to common shareholders - Basic 2,450 (628 ) 1,822 Net loss attributable to common shareholders - Diluted (954 ) (678 ) (1,632 ) Net income per basic share 0.09 (0.02 ) 0.07 Net loss per diluted share (0.03 ) (0.03 ) (0.06 ) Years Ended December 31, 2021 and 2020 2021 As reported Adjustment As corrected Net loss $ (7,635 ) $ (1,273 ) $ (8,908 ) Prepaid expenses and other current assets 2,802 (139 ) 2,663 Sales taxes payable - 1,412 1,412 2020 Net income 2,667 (684 ) 1,983 Prepaid expenses and other current assets 25 (75 ) (50 ) Sales taxes payable - 759 759

Note 3 - Fair Value Measureme_2

Note 3 - Fair Value Measurement (Tables)	12 Months Ended
Note 3 - Fair Value Measurement (Tables)	Dec. 31, 2022
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	As of December 31, 2022 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market accounts $ 11,416 $ - $ - $ 11,416 Available-for-sale securities: U.S. government securities 15,051 - - 15,051 Corporate debt securities - 26,047 - 26,047 Other debt securities - 3,494 - 3,494 Total 26,467 29,541 - 56,008 Liabilities: Contingent consideration - business combinations - - 4,456 4,456 Debt - 25,607 - 25,607 Total $ - $ 25,607 $ 4,456 $ 30,063 As of December 31, 2021 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 63,873 $ - $ - $ 63,873 Total 63,873 - - 63,873 Liabilities: Contingent consideration - business combinations - - 10,027 10,027 Total $ - $ - $ 10,027 $ 10,027
Contingent Consideration Liabilities [Member]
Notes Tables
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Year Ended December 31, (In thousands) 2022 2021 2020 Beginning balance as of December 31, 2021, 2020, and 2019 $ 10,027 $ 7,152 1,914 Additions - - 3,663 Change in fair value recognized in net (loss) income (4,754 ) 2,875 1,575 Payment of contingent consideration earned (817 ) - - Ending balance $ 4,456 $ 10,027 $ 7,152 (In thousands) 2021 2020 Beginning balance as of December 31, 2020 and 2019 $ 2,780 39,602 Exercised warrants (2,901 ) (33,221 ) Change in fair value recognized in net (loss) income 121 (3,601 ) Ending balance $ - $ 2,780

Note 4 - Investments (Tables)

Note 4 - Investments (Tables)	12 Months Ended
Note 4 - Investments (Tables)	Dec. 31, 2022
Notes Tables
Debt Securities, Available-for-Sale [Table Text Block]	December 31, 2022 Amortized Gross unrealized Estimated (In thousands) Cost Gains Losses Fair Value Available-for-sale securities, current portion U.S. government securities $ 15,087 $ 1 $ 37 $ 15,051 Corporate debt securities 26,057 6 16 26,047 Other debt securities 2,169 - 7 2,162 Total short-term 43,313 7 60 43,260 Available-for-sale securities, long-term Other debt securities 1,329 3 - 1,332 Total marketable securities $ 44,642 $ 10 $ 60 $ 44,592 Amortized Estimated (In thousands) Cost Fair Value Due in one year or less $ 43,313 $ 43,260 Due after one year through five years 1,329 1,332 Total $ 44,642 $ 44,592

Note 5 - Inventories (Tables)

Note 5 - Inventories (Tables)	12 Months Ended
Note 5 - Inventories (Tables)	Dec. 31, 2022
Notes Tables
Schedule of Inventory, Current [Table Text Block]	(In thousands) 2022 2021 Raw materials $ 20,950 $ 17,252 Work in progress 5,680 5,015 Finished goods 8,274 6,078 Total $ 34,904 $ 28,345

Note 6 - Leases (Tables)

Note 6 - Leases (Tables)	12 Months Ended
Note 6 - Leases (Tables)	Dec. 31, 2022
Notes Tables
Lessee, Operating and Finance Lease Term And Discount Rate [Table Text Block]	2022 2021 Weighted average discount rate - operating leases 4.2 % 3.8 % Weighted average discount rate - finance leases 6.1 % 6.1 % Weighted average remaining lease term in years - operating leases 7.2 7.8 Weighted average remaining lease term in years - finance leases 2.0 3.0
Lease, Cost [Table Text Block]	Year Ended December 31, (In thousands) 2022 2021 2020 Operating lease costs $ 3,701 $ 2,817 $ 839 Short-term lease costs 2,141 1,727 277 Total operating lease costs 5,842 4,544 1,116 Variable lease costs 1,104 749 357 Total lease expense $ 6,946 $ 5,293 $ 1,473
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	(In thousands) Operating Leases Financing Leases 2023 $ 3,448 $ 171 2024 3,089 101 2025 2,649 28 2026 2,267 2 2027 2,242 - Thereafter 6,927 - Total lease payments 20,622 302 Less: interest (2,800 ) (18 ) Total present value of lease liabilities $ 17,822 $ 284

Note 7 - Assets Held for Rent (

Note 7 - Assets Held for Rent (Tables)	12 Months Ended
Note 7 - Assets Held for Rent (Tables)	Dec. 31, 2022
Notes Tables
Scheduleof Assets Held for Rent [Table Text Block]	(In thousands) 2022 2021 Shippers placed in service $ 7,671 $ 5,645 Fixed assets held for rent 4,686 4,040 Accumulated depreciation (4,952 ) (2,272 ) Net 7,405 7,413 Shippers and related components in production 1,659 2,396 Total $ 9,064 $ 9,809

Note 8 - Property and Equipme_2

Note 8 - Property and Equipment (Tables)	12 Months Ended
Note 8 - Property and Equipment (Tables)	Dec. 31, 2022
Notes Tables
Property, Plant and Equipment [Table Text Block]	(In thousands) 2022 2021 Property and equipment Leasehold improvements $ 5,249 $ 3,840 Furniture and computer equipment 1,908 1,861 Manufacturing and other equipment 20,557 16,675 Construction in-progress 5,095 2,022 Subtotal 32,809 24,398 Less: Accumulated depreciation (9,171 ) (6,741 ) Net property and equipment $ 23,638 $ 17,657

Note 9 - Accrued Expenses and_2

Note 9 - Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Other Current Liabilities [Table Text Block]	(In thousands) 2022 2021 Accrued expenses $ 3,128 $ 1,656 Accrued taxes 975 27 Accrued compensation 5,080 4,351 Deferred revenue, current 548 814 Other 51 22 Total accrued expenses and other current liabilities $ 9,782 $ 6,870

Note 10 - Warranty Reserve Li_2

Note 10 - Warranty Reserve Liability (Tables)	12 Months Ended
Note 10 - Warranty Reserve Liability (Tables)	Dec. 31, 2022
Notes Tables
Schedule of Product Warranty Liability [Table Text Block]	(In thousands) 2022 2021 2020 Beginning balance as of December 31, 2021, 2020, and 2019 $ 9,398 $ 212 $ 191 Warranty reserve acquired in the acquisition of Global Cooling - 3,353 - Provision for warranties⁽¹⁾ 4,463 10,989 137 Settlements of warranty claims⁽¹⁾ (5,549 ) (5,156 ) (116 ) Ending Balance 8,312 9,398 212

Note 11 - Goodwill and Intang_2

Note 11 - Goodwill and Intangible Assets (Tables)	12 Months Ended
Note 11 - Goodwill and Intangible Assets (Tables)	Dec. 31, 2022
Notes Tables
Schedule of Goodwill [Table Text Block]	(In thousands) Goodwill Balance as of December 31, 2020 $ 58,449 Goodwill related to Global Cooling acquisition 137,822 Goodwill related to Sexton acquisition 28,470 Balance as of December 31, 2022 and 2021 224,741
Schedule of Finite-Lived Intangible Assets [Table Text Block]	(In thousands, except weighted average useful life) December 31, 2022 Intangible assets: Gross Carrying Value Accumulated Amortization Net Carrying Value Weighted Average Useful Life (in years) Customer Relationships $ 11,288 $ (3,993 ) $ 7,295 9.3 Tradenames 13,731 (4,323 ) 9,408 12.8 Technology - acquired 27,892 (12,796 ) 15,096 4.9 Non-compete agreements 1,187 (898 ) 289 2.0 Total intangible assets $ 54,098 $ (22,010 ) $ 32,088 8.2 December 31, 2021 Intangible assets: Gross Carrying Value Accumulated Amortization Net Carrying Value Weighted Average Useful Life (in years) Customer Relationships $ 17,516 $ (1,776 ) $ 15,740 10.3 Tradenames 35,574 (2,306 ) 33,268 13.8 Technology - acquired 41,942 (7,789 ) 34,153 5.9 Non-compete agreements 1,990 (442 ) 1,548 3.0 In-process research and development⁽¹⁾ 67,440 - 67,440 N/A Total intangible assets $ 164,462 $ (12,313 ) $ 152,149 9.8
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	(In thousands) For the Years Ending December 31, Estimated Amortization Expense 2023 $ 5,431 2024 4,606 2025 4,434 2026 4,136 2027 3,382 Thereafter 10,099 Total $ 32,088

Note 13 - Line of Credit and _2

Note 13 - Line of Credit and Long-term Debt (Tables)	12 Months Ended
Note 13 - Line of Credit and Long-term Debt (Tables)	Dec. 31, 2022
Notes Tables
Schedule of Debt [Table Text Block]	December 31, (In thousands) Maturity Date Interest Rate 2022 2021 2022 term loan 1 ⁽¹⁾ 4.0 % $ - $ 1,750 2022 term loan 2 Various 4.0 % 2,896 2,813 2022 term loan 3 Jun-26 6.8 % 20,000 - Insurance premium financing Apr-23 5.0 % 1,074 373 Freezer equipment loan Dec-25 5.7 % 466 612 Manufacturing equipment loans Oct-25 5.7 % 266 355 Freezer installation loan Various 6.3 % 1,078 1,334 Other loans Various Various 6 9 Total debt, excluding unamortized debt issuance costs 25,786 7,246 Less: unamortized debt issuance costs (179 ) (31 ) Total debt 25,607 7,215 Less: current portion of debt (1,814 ) (862 ) Total long-term debt $ 23,793 $ 6,353
Schedule of Maturities of Long-Term Debt [Table Text Block]	(In thousands) Amount 2023 $ 1,881 2024 5,544 2025 10,543 2026 5,221 2027 2,597 Thereafter - Total $ 25,786

Note 14 - Warrants (Tables)

Note 14 - Warrants (Tables)	12 Months Ended
Note 14 - Warrants (Tables)	Dec. 31, 2022
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	2021 2020 Shares Wtd. Avg. Exercise Price Shares Wtd. Avg. Exercise Price Outstanding at beginning of year 79,100 $ 4.75 3,959,005 $ 4.33 Exercised (79,100 ) 4.75 (3,879,905 ) 4.33 Outstanding and exercisable at end of year - $ - 79,100 $ 4.75

Note 15 - Stock-based Compens_2

Note 15 - Stock-based Compensation (Tables)	12 Months Ended
Note 15 - Stock-based Compensation (Tables)	Dec. 31, 2022
Notes Tables
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	2022 2021 Shares Wtd. Avg. Exercise Price Shares Wtd. Avg. Exercise Price Outstanding as of beginning of year 624,531 $ 2.13 844,455 $ 2.00 Exercised (161,646 ) 2.00 (183,064 ) 1.61 Forfeited - - (1,146 ) 5.69 Expired (6,592 ) 3.22 (35,714 ) 1.73 Outstanding at end of year 456,293 $ 2.17 624,531 $ 2.13 Stock options exercisable at year end 456,293 $ 2.17 624,531 $ 2.13 2021 Shares Wtd. Avg. Exercise Price Outstanding as of beginning of year 686,001 $ 1.64 Exercised (686,001 ) 1.64 Outstanding at end of year - $ 1.64 Stock options exercisable at year end - $ -
Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Range of Exercise Prices Number Outstanding at December 31, 2022 Weighted Average Remaining Contractual Life Weighted Average Exercise Price $1.00 - 1.50 2,000 3.85 $ 1.49 $1.51 - 2.00 177,500 3.28 1.90 $2.01 - 2.50 255,938 2.35 2.06 $2.51 - 8.60 20,855 4.92 5.69 456,293 2.84 $ 2.16
Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]	2022 2021 Shares Wtd. Avg. Grant Date Fair Value Shares Wtd. Avg. Grant Date Fair Value Outstanding as of beginning of year 1,212,783 $ 37.48 930,854 $ 19.31 Granted 1,373,909 25.26 801,484 47.20 Vested (569,535 ) 35.51 (378,502 ) 19.31 Forfeited (137,942 ) 40.19 (141,053 ) 36.95 Non-vested at year end 1,879,215 $ 28.94 1,212,783 $ 37.48 2022 2021 Shares Wtd. Avg. Grant Date Fair Value Shares Wtd. Avg. Grant Date Fair Value Outstanding as of beginning of year 139,756 $ 19.86 224,774 $ 19.20 Granted 349,568 22.66 152,665 32.50 Vested (218,280 ) 10.95 (231,268 ) 26.98 Forfeited - - (6,415 ) 40.65 Non-vested at year end 271,044 $ 30.64 139,756 $ 19.86
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	2022 2021 2020 Research and development costs $ 3,176 $ 1,906 $ 1,012 Sales and marketing costs 3,649 1,788 852 General and administrative costs 14,066 8,061 3,518 Cost of revenue 4,443 2,201 599 Total $ 25,334 $ 13,956 $ 5,981

Note 16 - Income Taxes (Tables)

Note 16 - Income Taxes (Tables)	12 Months Ended
Note 16 - Income Taxes (Tables)	Dec. 31, 2022
Notes Tables
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	Year Ended December 31, (In thousands) 2022 2021 2020 Domestic $ (146,091 ) $ (28,590 ) $ (1,281 ) Foreign 1,264 (436 ) - Total $ (144,827 ) $ (29,026 ) $ (1,281 )
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Year Ended December 31, (In thousands) 2022 2021 2020 Current: Federal $ - $ - $ - State 11 - 33 Foreign 205 9 - Total current tax provision 216 9 33 Deferred: Federal (2,924 ) (17,703 ) (3,297 ) State (2,314 ) (2,424 ) - Foreign - - - Total deferred tax benefit (5,238 ) (20,127 ) (3,297 ) Income tax benefit $ (5,022 ) $ (20,118 ) $ (3,264 )
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended December 31, 2022 2021 2020 Federal statutory tax 21 % 21 % 21 % State tax, net of federal benefit 3 % 7 % 20 % Stock compensation - 36 % 251 % Sec. 162(m) limitation on executive compensation (1 %) (11 %) (16 %) Fair value change in contingent consideration 1 % (2 %) (38 %) Fair value change in warrant liability - - 59 % Transaction costs - (1 %) (3 %) Gain on stock acquisition - 5 % - Tax credits 1 % - 6 % Change in valuation allowance (21 %) 20 % 4 % Expired net operating losses - (5 %) (47 %) Other - (1 %) (2 %) Total 4 % 69 % 255 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	(In thousands) 2022 2021 Deferred tax assets related to: Net operating loss carryforwards $ 29,102 $ 27,500 Stock-based compensation 3,207 2,066 Accruals and reserves 3,724 3,402 Inventory 425 236 Lease liabilities 3,653 4,198 Tax credit carryforward 1,423 594 Capitalized research and development 2,405 - Other 445 318 Total deferred tax assets 44,384 38,314 Deferred tax liabilities related to: Intangibles (6,150 ) (35,241 ) Right-of-use assets (3,458 ) (4,070 ) Fair value change in investments (447 ) (294 ) Fixed assets (1,177 ) (1,203 ) Other - - Total deferred tax liabilities (11,232 ) (40,808 ) Net deferred tax (liabilities) assets before valuation allowance 33,152 (2,494 ) Less: valuation allowance (33,402 ) (2,993 ) Net deferred tax liabilities $ (250 ) $ (5,487 )
Summary of Valuation Allowance [Table Text Block]	(In thousands) 2022 2021 2020 Balance at January 1 $ 2,993 $ 8,498 $ 8,706 Deferred tax liabilities assumed through acquisitions - (8,498 ) (3,297 ) Charged to income tax expense 30,409 2,993 3,089 Balance at December 31 $ 33,402 $ 2,993 $ 8,498
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	(In thousands) 2022 2021 Balance at January 1 $ 255 $ 96 Increase related to prior year tax positions 170 - Increase related to current year tax positions 185 159 Balance at December 31 $ 610 $ 255

Note 17 - Acquisitions (Tables)

Note 17 - Acquisitions (Tables)	12 Months Ended
Note 17 - Acquisitions (Tables)	Dec. 31, 2022
Notes Tables
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	Merger consideration shares 530,502 BioLife stock price (as of September 1, 2021) $ 60.50 Value of issued shares $ 32,095 plus: Fair value of BioLife’s existing investment in Sexton $ 7,951 less: Net working capital adjustment $ (118 ) Merger Consideration $ 39,928 BioLife shares outstanding (as of March 19, 2021) 33,401,359 Merger consideration percentage 19.9 % Merger consideration shares 6,646,870 less: Merger consideration shares withheld to satisfy outstanding GCI stockholder obligations to GCI 10,400 Subtotal 6,636,470 BioLife stock price (as of May 3, 2021) $ 35.07 Value of issued shares $ 232,741 plus: Settlement of BioLife prepaid deposits $ 2,152 plus: Net settlement of BioLife accounts receivable $ 16 Merger Consideration $ 234,909 Cash consideration $ 15,000 Stock consideration 17,916 Contingent consideration 3,663 Working capital adjustment (53 ) Total consideration transferred $ 36,526
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Cash $ 1,516 Accounts receivable, net 492 Inventory 1,310 Prepaid expenses and other current assets 670 Property, plant and equipment, net 737 Operating lease right-of-use assets, net 470 Developed technology 4,132 Customer relationships 2,276 Tradenames 2,324 Non-compete agreements 90 Goodwill 28,470 Accounts payable (291 ) Lease liabilities, operating (470 ) Deferred tax liability (1,482 ) Other liabilities (316 ) Fair value of net assets acquired $ 39,928 Cash $ 43 Accounts receivable, net 7,076 Inventory 15,547 Prepaid expenses and other current assets 639 Property, plant and equipment, net 3,512 Operating lease right-of-use assets, net 1,741 Financing lease right-of-use assets, net 114 Long-term deposits and other assets 4 Developed technology 18,140 Customer relationships 7,020 Tradenames 26,640 Non-compete agreements 1,240 In-process research and development 67,440 Goodwill 137,822 Accounts payable (9,837 ) Line of credit (4,231 ) Lease liabilities, operating (1,880 ) Lease liabilities, financing (114 ) Long-term debt (4,410 ) Deferred tax liability (24,133 ) Other liabilities (7,464 ) Fair value of net assets acquired $ 234,909 Cash $ 500 Accounts receivable, net 945 Prepaid expenses and other current assets 31 Property, plant and equipment, net 3,400 Customer relationships 7,420 Tradenames 4,020 Non-compete agreements 660 Goodwill 24,943 Other assets 1,547 Accounts payable (885 ) Deferred tax liability (3,297 ) Other liabilities (2,758 ) Fair value of net assets acquired $ 36,526
Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]	Fair Value Useful Life (Years) Developed technology $ 4,132 5 - 9 Customer relationships 2,276 2 Tradenames 2,324 11 Non-compete agreements 90 1 Total identifiable intangible assets $ 8,822 Fair Value Useful Life (Years) Developed technology $ 18,140 6 Customer relationships 7,020 12 Tradenames 26,640 15 Non-compete agreements 1,240 4 In-process research and development 67,440 N/A Total identifiable intangible assets $ 120,480 Fair Value Useful Life (Years) Customer relationships $ 7,420 14 Tradenames 4,020 19 Non-compete agreements 660 4 Total identifiable intangible assets $ 12,100
Business Acquisition, Pro Forma Information [Table Text Block]	2021 2020 (In thousands) (unaudited) (unaudited) Total revenue $ 122,494 $ 50,856 Net loss $ (9,860 ) $ (1,028 ) 2021 2020 (In thousands) (unaudited) (unaudited) Total revenue $ 143,732 $ 87,370 Net income (loss) $ (16,375 ) $ 501 2020 (In thousands) (unaudited) Total revenue $ 52,613 Net income $ 1,798

Note 1 - Organization and Sig_3

Note 1 - Organization and Significant Accounting Policies (Details Textual)			1 Months Ended	12 Months Ended
	Apr. 29, 2020 USD ($)	Apr. 20, 2020 USD ($)	Jun. 30, 2021 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Nov. 30, 2020 USD ($)	Jun. 30, 2020 USD ($)
Number of Reportable Segments				1
Number of Reporting Units				1
Contract with Customer, Liability, Revenue Recognized				$ 511,000
Business Combination, Contingent Consideration, Liability, Total						$ 221,000		$ 388,000
Impairment of Intangible Assets (Excluding Goodwill), Total				110,400,000	$ 0	0
Unrecognized Tax Benefits, Ending Balance				610,000	255,000	96,000
Advertising Expense				$ 768,000	$ 552,000	$ 167,000
Customer Concentration Risk [Member] \| Revenue Benchmark [Member] \| One Customer [Member]
Concentration Risk, Percentage				18%	17%	13%
Customer Concentration Risk [Member] \| Accounts Receivable [Member]
Number of Major Customers				2	2
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| Two Customers [Member]
Concentration Risk, Percentage				26%	32%
Supplier Concentration Risk [Member] \| Accounts Payable [Member]
Number of Suppliers				1
Supplier Concentration Risk [Member] \| Accounts Payable [Member] \| One Supplier [Member]
Concentration Risk, Percentage				23%	10%
Tax Attributes Carried Forward [Member]
Unrecognized Tax Benefits, Ending Balance				$ 610,000
Assets Held for Rent [Member]
Property, Plant and Equipment, Useful Life (Year)				3 years
Impairment of Intangible Assets (Excluding Goodwill), Total				$ 0	$ 0	$ 0
Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)				3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)				10 years
Contingent Convertible Preferred Stock [Member] \| Series A-1 and A-2, Preferred Stock [Member]
Equity Securities without Readily Determinable Fair Value, Amount				$ 4,100,000	3,400,000
Contingent Convertible Preferred Stock [Member] \| Series E Preferred Stock [Member]
Equity Securities without Readily Determinable Fair Value, Amount				995,000	995,000
Contingent Convertible Preferred Stock [Member] \| Series E Preferred Stock [Member] \| PanTHERA Cryosolutions Investment [Member]
Equity Securities without Readily Determinable Fair Value, Amount					995,000
Contingent Convertible Preferred Stock [Member] \| Series A-2 Preferred Stock [Member]
Equity Securities without Readily Determinable Fair Value, Amount							$ 1,000,000
Contingent Convertible Preferred Stock [Member] \| Preferred Stock, Class E [Member]
Contingent Milestone Payment						2,000,000
Contingent Millstone Payment, #1			$ 200,000
Contingent Convertible Preferred Stock [Member] \| Preferred Stock, Class E [Member] \| PanTHERA Cryosolutions Investment [Member]
Equity Securities without Readily Determinable Fair Value, Amount							$ 995,000
Convertible Debt Securities [Member]
Debt Securities, Gain (Loss), Total				697,000	0	1,300,000
Paycheck Protection Program CARES Act [Member]
Proceeds from Issuance of Debt		$ 2,175,320		0	0	2,175,000
Repayments of Debt	$ 2,175,320			$ 0	$ 0	$ 2,175,000

Note 1 - Organization and Sig_4

Note 1 - Organization and Significant Accounting Policies - Revenues By Product Line (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	[1]	Dec. 31, 2020	[2]
Total revenue	$ 161,759	$ 119,156		$ 48,087
Product, Freezer and Thaw [Member]
Total revenue	66,682	56,620		13,548
Product, Cell Processing [Member]
Total revenue	68,509	44,965		30,946
Product, Storage and Cold Chain Services [Member]
Total revenue	809	328		46
Service, Freezer and Thaw [Member]
Total revenue	74	0		0
Service, Storage and Cold Chain Services [Member]
Total revenue	15,234	9,817		1,752
Rental, Storage and Cold Chain Services [Member]
Total revenue	$ 10,451	$ 7,426		$ 1,795

[1]2021 revenue includes product revenue related to Global Cooling from May 3, 2021 through December 31, 2021 and product revenue related to Sexton from September 1, 2021 through December 31, 2021.[2]2020 revenue includes service revenue related to SciSafe from October 1, 2020 through December 31, 2020.

Note 1 - Organization and Sig_5

Note 1 - Organization and Significant Accounting Policies - Summary of Remaining Performance Obligations (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Rental Revenue [Member]
Revenue, expected to be recognized in the future	$ 4,635
Service Revenue [Member]
Revenue, expected to be recognized in the future	$ 210

Note 1 - Organization and Sig_6

Note 1 - Organization and Significant Accounting Policies - Summary of Remaining Performance Obligations 2 (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Rental Revenue [Member]
Revenue, expected to be recognized in the future	$ 4,635
Service Revenue [Member]
Revenue, expected to be recognized in the future	210
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 \| Rental Revenue [Member]
Revenue, expected to be recognized in the future	$ 3,735
Revenue, expected to be recognized in the future, period (Year)	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 \| Service Revenue [Member]
Revenue, expected to be recognized in the future	$ 200
Revenue, expected to be recognized in the future, period (Year)	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 \| Rental Revenue [Member]
Revenue, expected to be recognized in the future	$ 900
Revenue, expected to be recognized in the future, period (Year)	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 \| Service Revenue [Member]
Revenue, expected to be recognized in the future	$ 10
Revenue, expected to be recognized in the future, period (Year)	1 year

Note 1 - Organization and Sig_7

Note 1 - Organization and Significant Accounting Policies - Calculation of Basic and Diluted Shares (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020
Net (loss) income	$ (139,805)	$ (8,908)	[1]	$ 1,983	[1]
Amount attributable to unvested restricted shares	0	0		(100)
Amount attributable to warrants outstanding	0	0		(61)
Net (loss) income allocated to common shareholders	$ (139,805)	$ (8,908)		$ 1,822
Basic and Diluted (in shares)	42,481,027	38,503,944		27,306,258
Basic (in dollars per share)	$ (3.29)	$ (0.23)		$ 0.07
Amount attributable to warrants	$ 0	$ 0		$ (14)
Less: gain related to change in fair value of warrants	0	0		(3,601)
Net loss allocated to common shareholders	$ (139,805)	$ (8,908)		$ (1,632)
Diluted (in dollars per share)	$ (3.29)	$ (0.23)		$ (0.06)

[1]The Consolidated Statements of Comprehensive (Loss) Income for the years ended December 31, 2021 and 2020 were adjusted by the impact to net (loss) income noted here. Comprehensive loss for the year ended December 31, 2021 is now reported at $9.2 million, reflecting an adjustment of $1.3 million, and was previously reported as $7.9 million. Comprehensive income for the year ended December 31, 2020 is now reported at $1.9 million, reflecting an adjustment of negative $684,000, and was previously reported as $2.7 million.

Note 1 - Organization and Sig_8

Note 1 - Organization and Significant Accounting Policies - Anti-dilutive (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Anti-dilutive securities (in shares)	1,655,949	3,631,747
Share-based Payment Arrangement, Option and Restricted Stock Awards [Member]
Anti-dilutive securities (in shares)	1,637,745	2,131,794
Warrant [Member]
Anti-dilutive securities (in shares)	18,204	1,499,953

Note 1 - Organization and Sig_9

Note 1 - Organization and Significant Accounting Policies - Summary of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Cash and cash equivalents	$ 19,442	$ 69,860
Restricted cash	31	10
Total cash, cash equivalents, and restricted cash	$ 19,473	$ 69,870

Note 1 - Organization and Si_10

Note 1 - Organization and Significant Accounting Policies - Concentrations Risk by Geographic Locations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Long-Lived Assets	$ 48,266	$ 46,611
UNITED STATES
Long-Lived Assets	42,829	40,708
NETHERLANDS
Long-Lived Assets	$ 5,437	$ 5,903
Revenue Benchmark [Member] \| Product Concentration Risk [Member] \| CryoStor Products [Member]
Revenue	36%	33%	60%
Revenue Benchmark [Member] \| Product Concentration Risk [Member] \| 780XLE Freezer Line [Member]
Revenue	22%	22%	0%
Revenue Benchmark [Member] \| Geographic Concentration Risk [Member] \| UNITED STATES
Revenue	72%	78%	73%
Revenue Benchmark [Member] \| Geographic Concentration Risk [Member] \| CANADA
Revenue	17%	7%	13%
Revenue Benchmark [Member] \| Geographic Concentration Risk [Member] \| EMEA [Member]
Revenue	7%	14%	12%
Revenue Benchmark [Member] \| Geographic Concentration Risk [Member] \| Geographic, Other [Member]
Revenue	4%	1%	2%
Revenue Benchmark [Member] \| Geographic Concentration Risk [Member] \| All Location [Member]
Revenue	100%	100%	100%

Note 2 - Revision of Previous_3

Note 2 - Revision of Previously Issued Consolidated Financial Statements (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020	Dec. 31, 2019
Retained Earnings (Accumulated Deficit), Total	$ (246,915,000)	$ (107,110,000)	[1]		$ 100,200,000
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Total	$ (140,202,000)	(9,190,000)		$ 1,983,000
Revision of Prior Period, Adjustment [Member]
Retained Earnings (Accumulated Deficit), Total		(2,090,000)	[1]		(133,000)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Total		1,300,000		(684,000)
Previously Reported [Member]
Retained Earnings (Accumulated Deficit), Total		(105,020,000)	[1]		$ 100,100,000
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Total		(7,900,000)		2,700,000
Adjusted Balance [Member]
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Total				$ 1,900,000
Accrued Expenses and Other Current Liabilities [Member]
Taxes Payable, Total		$ 272,000

[1]The impact of the error on Accumulated deficit in our Consolidated Balance Sheet as of the year ended December 31, 2019 was negative $133,000, adjusting the ending balance to be $100.2 million when previously reported as $100.1 million.

Note 2 - Revision of Previous_4

Note 2 - Revision of Previously Issued Consolidated Financial Statements - Revisions to Financial Statements (Details) - USD ($)		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020		Dec. 31, 2019
Prepaid expenses and other current assets		$ 6,879,000	$ 4,656,000
Total current assets		138,452,000	126,088,000
Total assets		450,229,000	554,286,000
Accrued expenses and other current liabilities(1)		9,782,000	6,870,000	[1]
Sales taxes payable		4,151,000	2,591,000
Total current liabilities		44,582,000	42,700,000
Total liabilities		86,041,000	76,239,000
Retained Earnings (Accumulated Deficit), Total		(246,915,000)	(107,110,000)	[2]			$ 100,200,000
Total shareholders’ equity		364,188,000	478,047,000		$ 204,429,000		43,321,000
Total liabilities and shareholders’ equity		450,229,000	554,286,000
General and administrative		47,670,000	33,668,000		15,273,000
Total operating expenses		307,300,000	154,316,000		54,328,000
Operating loss		(145,541,000)	(35,160,000)		(6,241,000)
Interest (expense) income, net		(687,000)	(485,000)		40,000
Total other income, net		714,000	6,134,000		4,960,000
Loss before income tax benefit		(144,827,000)	(29,026,000)		(1,281,000)
Net (loss) income		$ (139,805,000)	$ (8,908,000)	[3]	$ 1,983,000	[3]
Net income (loss) per basic share (in dollars per share)		$ (3.29)	$ (0.23)		$ 0.07
Net loss per diluted share (in dollars per share)		$ (3.29)	$ (0.23)		$ (0.06)
Net income attributable to common shareholders - Basic		$ (139,805,000)	$ (8,908,000)		$ 1,822,000
Net loss attributable to common shareholders - Diluted		(139,805,000)	(8,908,000)		(1,632,000)
Net (loss) income		(139,805,000)	(8,908,000)	[3]	1,983,000	[3]
Prepaid expenses and other current assets		26,000	2,663,000		(50,000)
Sales taxes payable		$ 1,526,000	1,412,000		759,000
Previously Reported [Member]
Prepaid expenses and other current assets			4,427,000
Total current assets			125,859,000
Total assets			554,057,000
Accrued expenses and other current liabilities(1)	[1]		7,142,000
Sales taxes payable			0
Total current liabilities			40,381,000
Total liabilities			73,920,000
Retained Earnings (Accumulated Deficit), Total			(105,020,000)	[2]			100,100,000
Total shareholders’ equity			480,137,000
Total liabilities and shareholders’ equity			554,057,000
General and administrative			32,448,000		14,607,000
Total operating expenses			153,096,000		53,662,000
Operating loss			(33,940,000)		(5,575,000)
Interest (expense) income, net			(432,000)		58,000
Total other income, net			6,187,000		4,978,000
Loss before income tax benefit			(27,753,000)		(597,000)
Net (loss) income	[3]		$ (7,635,000)		$ 2,667,000
Net income (loss) per basic share (in dollars per share)			$ (0.20)		$ 0.09
Net loss per diluted share (in dollars per share)			$ (0.20)		$ (0.03)
Net income attributable to common shareholders - Basic					$ 2,450,000
Net loss attributable to common shareholders - Diluted					(954,000)
Net (loss) income	[3]		$ (7,635,000)		2,667,000
Prepaid expenses and other current assets			2,802,000		25,000
Sales taxes payable			0		0
Revision of Prior Period, Adjustment [Member]
Prepaid expenses and other current assets			229,000
Total current assets			229,000
Total assets			229,000
Accrued expenses and other current liabilities(1)	[1]		(272,000)
Sales taxes payable			2,591,000
Total current liabilities			2,319,000
Total liabilities			2,319,000
Retained Earnings (Accumulated Deficit), Total			(2,090,000)	[2]			$ (133,000)
Total shareholders’ equity			(2,090,000)
Total liabilities and shareholders’ equity			229,000
General and administrative			1,220,000		666,000
Total operating expenses			1,220,000		666,000
Operating loss			(1,220,000)		(666,000)
Interest (expense) income, net			(53,000)		(18,000)
Total other income, net			(53,000)		(18,000)
Loss before income tax benefit			(1,273,000)		(684,000)
Net (loss) income	[3]		$ (1,273,000)		$ (684,000)
Net income (loss) per basic share (in dollars per share)			$ (0.03)		$ (0.02)
Net loss per diluted share (in dollars per share)			$ (0.03)		$ (0.03)
Net income attributable to common shareholders - Basic					$ (628,000)
Net loss attributable to common shareholders - Diluted					(678,000)
Net (loss) income	[3]		$ (1,273,000)		(684,000)
Prepaid expenses and other current assets			(139,000)		(75,000)
Sales taxes payable			$ 1,412,000		$ 759,000

[1]In the prior year Consolidated Balance Sheet as of the year ended December 31, 2021, accrued sales taxes in the amount of $272,000 were recorded within the Accrued expenses and other current liabilities line item on the consolidated balance sheets. These were reclassified to Sales tax payable in the current year.[2]The impact of the error on Accumulated deficit in our Consolidated Balance Sheet as of the year ended December 31, 2019 was negative $133,000, adjusting the ending balance to be $100.2 million when previously reported as $100.1 million.[3]The Consolidated Statements of Comprehensive (Loss) Income for the years ended December 31, 2021 and 2020 were adjusted by the impact to net (loss) income noted here. Comprehensive loss for the year ended December 31, 2021 is now reported at $9.2 million, reflecting an adjustment of $1.3 million, and was previously reported as $7.9 million. Comprehensive income for the year ended December 31, 2020 is now reported at $1.9 million, reflecting an adjustment of negative $684,000, and was previously reported as $2.7 million.

Note 3 - Fair Value Measureme_3

Note 3 - Fair Value Measurement (Details Textual)	12 Months Ended
Note 3 - Fair Value Measurement (Details Textual)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Oct. 01, 2020 USD ($)	Jun. 30, 2020 USD ($)
Business Combination, Contingent Consideration, Liability, Total			$ 221,000		$ 388,000
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	$ (4,754,000)	$ 2,875,000	$ 1,575,000
SciSafe Holdings, Inc [Member]
Business Combination, Contingent Consideration, Liability, Total	4,300,000	9,900,000		$ 3,700,000
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	$ 5,600,000	$ 3,000,000
Measurement Input, Discount Rate [Member] \| SciSafe Holdings, Inc [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.128			0.045
Measurement Input, Risk Free Interest Rate [Member] \| SciSafe Holdings, Inc [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.041			0.0020
Measurement Input, Asset Price Volatility [Member] \| SciSafe Holdings, Inc [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input				0.60
Measurement Input, Revenue Volatility [Member] \| SciSafe Holdings, Inc [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.30			0.15
Measurement Input Asset Volatility [Member] \| SciSafe Holdings, Inc [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.68
Measurement Input, Price Volatility [Member] \| Minimum [Member]
Warrants and Rights Outstanding, Measurement Input			0.568
Measurement Input, Price Volatility [Member] \| Maximum [Member]
Warrants and Rights Outstanding, Measurement Input			0.846
Convertible Debt Securities [Member] \| Minimum [Member]
Debt Securities, Term (Year)	1 year
Convertible Debt Securities [Member] \| Maximum [Member]
Debt Securities, Term (Year)	2 years
Convertible Debt Securities [Member] \| Measurement Input, Prepayment Rate [Member]
Debt Securities, Trading, Measurement Input	0.080
Convertible Debt Securities [Member] \| Measurement Input, Prepayment Rate [Member] \| Minimum [Member]
Debt Securities, Trading, Measurement Input	0.05
Convertible Debt Securities [Member] \| Measurement Input, Prepayment Rate [Member] \| Maximum [Member]
Debt Securities, Trading, Measurement Input		0.50

Note 3 - Fair Value Measureme_4

Note 3 - Fair Value Measurement - Financial Assets and Liabilities on Recurring Basis (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2020
Marketable debt securities	$ 44,592,000
Contingent consideration - business combinations			$ 221,000	$ 388,000
Fair Value, Recurring [Member]
Assets	56,008,000	$ 63,873,000
Contingent consideration - business combinations	4,456,000	10,027,000
Debt	25,607,000
Liabilities	30,063,000	10,027,000
Fair Value, Recurring [Member] \| US Government Agencies Debt Securities [Member]
Marketable debt securities	15,051,000
Fair Value, Recurring [Member] \| Other Debt Obligations [Member]
Marketable debt securities	3,494,000
Fair Value, Recurring [Member] \| Money Market Funds [Member]
Cash equivalents	11,416,000	63,873,000
Fair Value, Recurring [Member] \| Corporate Debt Securities, Cash Equivalents [Member]
Cash equivalents	26,047,000
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member]
Assets	26,467,000	63,873,000
Contingent consideration - business combinations	0	0
Debt	0
Liabilities	0	0
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member] \| US Government Agencies Debt Securities [Member]
Marketable debt securities	15,051,000
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member] \| Other Debt Obligations [Member]
Marketable debt securities	0
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member] \| Money Market Funds [Member]
Cash equivalents	11,416,000	63,873,000
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member] \| Corporate Debt Securities, Cash Equivalents [Member]
Cash equivalents	0
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member]
Assets	29,541,000	0
Contingent consideration - business combinations	0	0
Debt	25,607,000
Liabilities	25,607,000	0
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member] \| US Government Agencies Debt Securities [Member]
Marketable debt securities	0
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member] \| Other Debt Obligations [Member]
Marketable debt securities	3,494,000
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member] \| Money Market Funds [Member]
Cash equivalents	0	0
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member] \| Corporate Debt Securities, Cash Equivalents [Member]
Cash equivalents	26,047,000
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member]
Assets	0	0
Contingent consideration - business combinations	4,456,000	10,027,000
Debt	0
Liabilities	4,456,000	10,027,000
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member] \| US Government Agencies Debt Securities [Member]
Marketable debt securities	0
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member] \| Other Debt Obligations [Member]
Marketable debt securities	0
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member] \| Money Market Funds [Member]
Cash equivalents	0	$ 0
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member] \| Corporate Debt Securities, Cash Equivalents [Member]
Cash equivalents	$ 0

Note 3 - Fair Value Measureme_5

Note 3 - Fair Value Measurement - Fair Value of Contingent Consideration Using Level 3 Inputs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Contingent Consideration Liabilities [Member]
Balance	$ 10,027	$ 7,152	$ 1,914
Additions	0	0	3,663
Change in fair value recognized in net (loss) income	(4,754)	2,875	1,575
Payment of contingent consideration earned	(817)	0	0
Balance	4,456	10,027	7,152
Exercised warrants	817	0	0
Warrant Liabilities [Member]
Balance	2,780	39,602
Change in fair value recognized in net (loss) income	121	(3,601)
Payment of contingent consideration earned	2,901	33,221
Balance	0	2,780	$ 39,602
Exercised warrants	$ (2,901)	$ (33,221)

Note 4 - Investments (Details T

Note 4 - Investments (Details Textual) - Contingent Convertible Preferred Stock [Member] - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Series A-1 and A-2, Preferred Stock [Member]
Equity Securities without Readily Determinable Fair Value, Amount	$ 4,100,000	$ 3,400,000
Series E Preferred Stock [Member]
Equity Securities without Readily Determinable Fair Value, Amount	$ 995,000	$ 995,000

Note 4 - Investments - Availabl

Note 4 - Investments - Available-For-Sale Marketable Securities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Debt Securities, Available-for-Sale, Amortized Cost, Current	$ 43,313
Debt Securities, Available-for-Sale, Unrealized Gain, Current	7
Debt Securities, Available-for-Sale, Unrealized Loss, Current	60
Available-for-sale securities, current portion	43,260	$ 0
Debt Securities, Available-for-Sale, Amortized Cost, NoncurrentDebt Securities, Available-for-Sale, Amortized Cost, Noncurrent	1,329
Available-for-sale securities, long term	1,332	0
Debt Securities, Available-for-Sale, Amortized Cost, Total	44,642
Debt Securities, Available-for-Sale, Unrealized Gain	10
Debt Securities, Available-for-Sale, Unrealized Loss	60
Debt Securities, Available-for-Sale, Total	44,592
Due in one year or less	43,313
Due in one year or less	43,260	$ 0
Due after one year through five years	1,329
Due after one year through five years	1,332
Total	44,642
Marketable debt securities	44,592
US Government Agencies Debt Securities [Member]
Debt Securities, Available-for-Sale, Amortized Cost, Current	15,087
Debt Securities, Available-for-Sale, Unrealized Gain, Current	1
Debt Securities, Available-for-Sale, Unrealized Loss, Current	37
Available-for-sale securities, current portion	15,051
Due in one year or less	15,087
Due in one year or less	15,051
Corporate Debt Securities [Member]
Debt Securities, Available-for-Sale, Amortized Cost, Current	26,057
Debt Securities, Available-for-Sale, Unrealized Gain, Current	6
Debt Securities, Available-for-Sale, Unrealized Loss, Current	16
Available-for-sale securities, current portion	26,047
Due in one year or less	26,057
Due in one year or less	26,047
Other Debt Obligations [Member]
Debt Securities, Available-for-Sale, Amortized Cost, Current	2,169
Debt Securities, Available-for-Sale, Unrealized Gain, Current	0
Debt Securities, Available-for-Sale, Unrealized Loss, Current	7
Available-for-sale securities, current portion	2,162
Debt Securities, Available-for-Sale, Amortized Cost, NoncurrentDebt Securities, Available-for-Sale, Amortized Cost, Noncurrent	1,329
Debt Securities, Available-for-Sale, Unrealized Gain, Noncurrent	3
Debt Securities, Available-for-Sale, Unrealized Loss, Noncurrent	0
Available-for-sale securities, long term	1,332
Due in one year or less	2,169
Due in one year or less	2,162
Due after one year through five years	$ 1,329

Note 5 - Inventories - Summary

Note 5 - Inventories - Summary of Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Raw materials	$ 20,950	$ 17,252
Work in progress	5,680	5,015
Finished goods	8,274	6,078
Total	$ 34,904	$ 28,345

Note 6 - Leases (Details Textua

Note 6 - Leases (Details Textual)	Dec. 31, 2022
Real Estate Lease[Member] \| Minimum [Member]
Lessee, Operating Lease, Remaining Lease Term (Year)	1 year
Lessee, Operating Lease, Renewal Term (Year)	1 year
Real Estate Lease[Member] \| Maximum [Member]
Lessee, Operating Lease, Remaining Lease Term (Year)	8 years
Lessee, Operating Lease, Renewal Term (Year)	5 years
Vehicle and Other Equipment {[Member] \| Minimum [Member]
Lessee, Operating Lease, Term of Contract (Year)	1 year
Vehicle and Other Equipment {[Member] \| Maximum [Member]
Lessee, Operating Lease, Term of Contract (Year)	5 years

Note 6 - Leases - Lease Term an

Note 6 - Leases - Lease Term and Discount Rate (Details)	Dec. 31, 2022	Dec. 31, 2021
Weighted average discount rate - operating leases	4.20%	3.80%
Weighted average discount rate - finance leases	6.10%	6.10%
Weighted average remaining lease term in years - operating leases (Year)	7 years 2 months 12 days	7 years 9 months 18 days
Weighted average remaining lease term in years - finance leases (Year)	2 years	3 years

Note 6 - Leases - Components of

Note 6 - Leases - Components of Lease Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Operating lease costs	$ 3,701	$ 2,817	$ 839
Short-term lease costs	2,141	1,727	277
Total operating lease costs	5,842	4,544	1,116
Variable lease costs	1,104	749	357
Total lease expense	$ 6,946	$ 5,293	$ 1,473

Note 6 - Leases - Maturities of

Note 6 - Leases - Maturities of Lease Liabilities (Details) $ in Thousands	Dec. 31, 2022 USD ($)
2023, operating leases	$ 3,448
2023, finance leases	171
2024, operating leases	3,089
2024, finance leases	101
2025, operating leases	2,649
2025, finance leases	28
2026, operating leases	2,267
2026, finance leases	2
2027, operating leases	2,242
2027, finance leases	0
Thereafter, operating leases	6,927
Thereafter, finance leases	0
Total operating lease payments	20,622
Total financing lease payments, finance leases	302
Less: operating lease interest	(2,800)
Less: financing lease interest	(18)
Total present value of operating lease liabilities	17,822
Total present value of financing lease liabilities	$ 284

Note 7 - Assets Held for Rent_2

Note 7 - Assets Held for Rent (Details Textual) - USD ($)	12 Months Ended
Note 7 - Assets Held for Rent (Details Textual) - USD ($)	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Assets Held for Rent, Depreciation	$ 3,500,000	$ 1,900,000	$ 671,000

Note 7 - Assets Held for Rent -

Note 7 - Assets Held for Rent - Assets Held for Rent (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Shippers placed in service	$ 7,671	$ 5,645
Fixed assets held for rent	4,686	4,040
Accumulated depreciation	(4,952)	(2,272)
Net	7,405	7,413
Shippers and related components in production	1,659	2,396
Total	$ 9,064	$ 9,809

Note 8 - Property and Equipme_3

Note 8 - Property and Equipment (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Depreciation, Total	$ 3.3	$ 2.9	$ 1.4

Note 8 - Property and Equipme_4

Note 8 - Property and Equipment - Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Property and equipment	$ 32,809	$ 24,398
Less: Accumulated depreciation	(9,171)	(6,741)
Net property and equipment	23,638	17,657
Leasehold Improvements [Member]
Property and equipment	5,249	3,840
Furniture and Computer Equipment [Member]
Property and equipment	1,908	1,861
Manufacturing Facility [Member]
Property and equipment	20,557	16,675
Construction in Progress [Member]
Property and equipment	$ 5,095	$ 2,022

Note 9 - Accrued Expenses and_3

Note 9 - Accrued Expenses and Other Current Liabilities - Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Accrued expenses	$ 3,128	$ 1,656
Accrued taxes	975	27
Accrued compensation	5,080	4,351
Deferred revenue, current	548	814
Other	51	22
Total accrued expenses and other current liabilities	$ 9,782	$ 6,870	[1]

[1]In the prior year Consolidated Balance Sheet as of the year ended December 31, 2021, accrued sales taxes in the amount of $272,000 were recorded within the Accrued expenses and other current liabilities line item on the consolidated balance sheets. These were reclassified to Sales tax payable in the current year.

Note 10 - Warranty Reserve Li_3

Note 10 - Warranty Reserve Liability (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Standard Product Warranty Accrual, Increase (Decrease) for Preexisting Warranties	$ 1.6	$ 1.1

Note 10 - Warranty Reserve Li_4

Note 10 - Warranty Reserve Liability - Warranty Reserve Liability (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Balance		$ 9,398	$ 212	$ 191
Warranty reserve acquired in the acquisition of Global Cooling		0	3,353	0
Provision for warranties	[1]	4,463	10,989	137
Settlements of warranty claims	[1]	(5,549)	(5,156)	(116)
Balance		$ 8,312	$ 9,398	$ 212

[1]Both the Provision for warranties and Settlements of warranty claims balances include reclassifications of $1.6 million and $1.1 million for the years ended December 31, 2022 and 2021, respectively, to reflect changes in warranty utilization on pre-existing claims.

Note 11 - Goodwill and Intang_3

Note 11 - Goodwill and Intangible Assets (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Sep. 30, 2022
Impairment of Intangible Assets (Excluding Goodwill), Total			$ 110,400,000	$ 0	$ 0
Amortization of Intangible Assets			9,697,000	8,202,000	$ 3,033,000
Finite-Lived Intangible Assets, Net, Ending Balance	$ 32,088,000		32,088,000
Abandoned In Process Research and Development [Member]
Impairment of Intangible Assets (Excluding Goodwill), Total		$ 8,000,000
In Process Research and Development Not Related to Abandonment [Member]
Impairment of Intangible Assets (Excluding Goodwill), Total		50,900,000	8,500,000
Technology-Based Intangible Assets [Member]
Impairment of Intangible Assets (Excluding Goodwill), Total	10,500,000	3,500,000
Finite-Lived Intangible Assets, Net, Ending Balance	15,096,000		15,096,000	34,153,000		$ 38,400,000
Customer Relationships [Member]
Impairment of Intangible Assets (Excluding Goodwill), Total	4,700,000	1,500,000
Finite-Lived Intangible Assets, Net, Ending Balance	7,295,000		7,295,000	15,740,000		16,000,000
Trade Names [Member]
Impairment of Intangible Assets (Excluding Goodwill), Total	15,900,000	5,900,000
Finite-Lived Intangible Assets, Net, Ending Balance	9,408,000		9,408,000	33,268,000		29,600,000
Noncompete Agreements [Member]
Impairment of Intangible Assets (Excluding Goodwill), Total	800,000	$ 4,000
Finite-Lived Intangible Assets, Net, Ending Balance	$ 289,000		$ 289,000	$ 1,548,000		$ 2,000,000

Note 11 - Goodwill and Intang_4

Note 11 - Goodwill and Intangible Assets - Goodwill (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($)
Balance	$ 58,449
Balance	224,741
Global Cooling[Member]
Goodwill related to acquisition	137,822
Sexton Biotechnologies, Inc. [Member]
Goodwill related to acquisition	$ 28,470

Note 11 - Goodwill and Intang_5

Note 11 - Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Sep. 30, 2022
Accumulated Amortization		$ (22,010)	$ (12,313)
Net Carrying Value		32,088
Total intangible assets, gross		54,098	164,462
Total intangible assets, net		$ 32,088	$ 152,149
Weighted Average [Member]
Weighted Average Useful Life (Year)		8 years 2 months 12 days	9 years 9 months 18 days
Customer Relationships [Member]
Gross Carrying Value		$ 11,288	$ 17,516
Accumulated Amortization		(3,993)	(1,776)
Net Carrying Value		$ 7,295	$ 15,740	$ 16,000
Customer Relationships [Member] \| Weighted Average [Member]
Weighted Average Useful Life (Year)		9 years 3 months 18 days	10 years 3 months 18 days
Trade Names [Member]
Gross Carrying Value		$ 13,731	$ 35,574
Accumulated Amortization		(4,323)	(2,306)
Net Carrying Value		$ 9,408	$ 33,268	29,600
Trade Names [Member] \| Weighted Average [Member]
Weighted Average Useful Life (Year)		12 years 9 months 18 days	13 years 9 months 18 days
Technology-Based Intangible Assets [Member]
Gross Carrying Value		$ 27,892	$ 41,942
Accumulated Amortization		(12,796)	(7,789)
Net Carrying Value		$ 15,096	$ 34,153	38,400
Technology-Based Intangible Assets [Member] \| Weighted Average [Member]
Weighted Average Useful Life (Year)		4 years 10 months 24 days	5 years 10 months 24 days
Noncompete Agreements [Member]
Gross Carrying Value		$ 1,187	$ 1,990
Accumulated Amortization		(898)	(442)
Net Carrying Value		$ 289	$ 1,548	$ 2,000
Noncompete Agreements [Member] \| Weighted Average [Member]
Weighted Average Useful Life (Year)		2 years	3 years
In Process Research and Development [Member]
Gross Carrying Value	[1]		$ 67,440
Accumulated Amortization	[1]		0
Net Carrying Value	[1]		$ 67,440

[1]In-process R&D represents the fair value of incomplete research and development that has not yet reached technological feasibility. Per discussion below, this balance has been written off as a result of the impairment analyses performed during the second and fourth quarters of the year ended December 31, 2022.

Note 11 - Goodwill and Intang_6

Note 11 - Goodwill and Intangible Assets - Future Amortization Expense (Details) $ in Thousands	Dec. 31, 2022 USD ($)
2023	$ 5,431
2024	4,606
2025	4,434
2026	4,136
2027	3,382
Thereafter	10,099
Total	$ 32,088

Note 12 - Commitments and Con_2

Note 12 - Commitments and Contingencies (Details Textual)	48 Months Ended
Note 12 - Commitments and Contingencies (Details Textual)	Dec. 31, 2022 USD ($)
Sales and Excise Tax Payable	$ 3,700,000
Sales Taxes Assessed	$ 306,000

Note 13 - Line of Credit and _3

Note 13 - Line of Credit and Long-term Debt (Details Textual) - USD ($) $ in Thousands		1 Months Ended
	Sep. 30, 2022	May 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Oct. 31, 2021
Long-term Debt, Gross			$ 25,786	$ 7,246
The 2022 Term Loan 3 [Member]
Long-term Debt, Gross			20,000	$ 0
Debt Instrument, Face Amount	$ 20,000		$ 20,000
Debt Instrument, Interest Rate, Stated Percentage			6.80%
Debt Instrument, Maximum Borrowing Capacity	50,000
Debt Instrument, Maximum Borrowing Capacity at Closing	30,000
Debt Instrument, Additional Maximum Amount Within Nine Months After Closing	10,000
Debt Instrument, Additional Maximum Amount Upon Certain Milestone Acheivements	10,000
Debt Instrument, Additional Maximum At Discretion of Lender	$ 10,000
Debt Instrument, Interest Rate, Maximum Stated Percentage for Each Tranche Borrowed	1%
Prime Rate [Member] \| The 2022 Term Loan 3 [Member]
Debt Instrument, Basis Spread on Variable Rate	0.50%
Line of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity		$ 5,000
Line of Credit [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate		5.50%
Notes Payable [Member]
Long-term Debt, Gross		$ 4,400
Notes Payable [Member] \| Advantage Term Note 1 [Member]
Debt Instrument, Face Amount					$ 1,400
Notes Payable [Member] \| Advantage Term Note 2 [Member]
Debt Instrument, Face Amount					1,400
Notes Payable [Member] \| Enhanced Term Note [Member]
Debt Instrument, Face Amount					$ 1,800
Debt Instrument, Interest Rate, Stated Percentage					4%
Notes Payable [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate		6.50%

Note 13 - Line of Credit and _4

Note 13 - Line of Credit and Long-term Debt - Long-term Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2022		Dec. 31, 2021
Debt, carrying amount	$ 25,786		$ 7,246
Less: unamortized debt issuance costs	(179)		(31)
Total debt	25,607		7,215
Less: current portion of debt	(1,814)		(862)
Total long-term debt	$ 23,793		6,353
The 2022 Term Loan 1 [Member]
Interest rate	4%
Debt, carrying amount	$ 0	[1]	1,750
The 2022 Term Loan 2 [Member]
Interest rate	4%
Debt, carrying amount	$ 2,896		2,813
The 2022 Term Loan 3 [Member]
Interest rate	6.80%
Debt, carrying amount	$ 20,000		0
Financed Insurance Premium [Member]
Interest rate	5%
Debt, carrying amount	$ 1,074		373
Freezer Equipment Loan [Member]
Interest rate	5.70%
Debt, carrying amount	$ 466		612
Manufacturing Equipment Loans [Member]
Interest rate	5.70%
Debt, carrying amount	$ 266		355
Freezer Installation Loan [Member]
Interest rate	6.30%
Debt, carrying amount	$ 1,078		1,334
Other Loans [Member]
Debt, carrying amount	6		9
Total Debt [Member]
Total long-term debt	$ 23,793		$ 6,353

[1](1) 2022 term loan 1 carried a maturity date of September 2024 as of the year ended December 31, 2021. As of September 30, 2022, the entirety of the outstanding principal and accrued interest was repaid.

Note 13 - Line of Credit and _5

Note 13 - Line of Credit and Long-term Debt - Maturities of Loans Payable (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
2023	$ 1,881
2024	5,544
2025	10,543
2026	5,221
2027	2,597
Thereafter	0
Total	25,607	$ 7,215
Total Scheduled Maturity [Member]
Total	$ 25,786

Note 14 - Warrants (Details Tex

Note 14 - Warrants (Details Textual) - shares			12 Months Ended		36 Months Ended
Note 14 - Warrants (Details Textual) - shares	Mar. 25, 2021	May 14, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2022
Class of Warrant or Right, Exercised During Period (in shares)			79,100	3,871,405	3,879,905
WAVI Holding AG and Taurus4757 GmbH Warrants [Member]
Stock Issued During Period, Shares, Cashless Warrant Exercises (in shares)		2,747,970
Class of Warrant or Right, Exercised During Period (in shares)		3,871,405
Warrants Exercised [Member]
Stock Issued During Period, Shares, Cashless Warrant Exercises (in shares)	70,030
Class of Warrant or Right, Exercised During Period (in shares)	79,100

Note 14 - Warrants - Summary of

Note 14 - Warrants - Summary of Warrant Activity (Details) - $ / shares	12 Months Ended		36 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2022
Balance (in shares)	79,100	3,959,005	3,959,005
Balance (in dollars per share)	$ 4.75	$ 4.33	$ 4.33
Exercised, number of shares (in shares)	(79,100)	(3,871,405)	(3,879,905)
Exercised, weighted average exercise price (in dollars per share)	$ 4.75		$ 4.33
Balance (in shares)	0	79,100
Balance (in dollars per share)	$ 0	$ 4.75

Note 15 - Stock-based Compens_3

Note 15 - Stock-based Compensation (Details Textual) - USD ($)							4 Months Ended	12 Months Ended
	Feb. 24, 2022	May 03, 2021	Feb. 08, 2021	Mar. 25, 2020	Apr. 01, 2019	Feb. 25, 2019	Aug. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2018	Dec. 31, 2017	Jun. 30, 2022	Jun. 30, 2021	Jul. 31, 2020	May 31, 2017	Dec. 31, 2013
Share-Based Payment Arrangement, Expense								$ 25,334,000	$ 13,956,000	$ 5,981,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)								2 years 10 months 2 days
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)								456,293	624,531	844,455
Share-Based Payment Arrangement, Expense								$ 0	$ 25,000	$ 119,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value								7,300,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value								7,300,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value								$ 4,100,000	$ 6,900,000	$ 13,100,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)								0	0	0
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)								3 years
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total								$ 0
Performance Shares [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)									0	686,001
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares)								1,879,215	1,212,783	930,854
Share-Based Payment Arrangement, Expense								$ 21,000,000	$ 12,700,000	$ 3,000,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)								1,373,909	801,484
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total								$ 47,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Fair Value								34,700,000	$ 37,800,000	15,300,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value								$ 12,600,000	$ 15,900,000	4,500,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)								3 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)								$ 25.26	$ 47.20
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)								569,535	378,502
Restricted Stock [Member] \| Executive Officer [Member]
Share-Based Payment Arrangement, Expense									$ 666,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)							21,566
Performance-based Restricted Stock [Member]
Share-Based Payment Arrangement, Expense								$ 0	0	760,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)				82,805
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)				$ 9.18
Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount								0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Aggregate Fair Value								0	0	$ 760,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested								$ 0	$ 2,300,000
Market-based Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares)								271,044	139,756	224,774
Share-Based Payment Arrangement, Expense								$ 4,300,000	$ 1,400,000	$ 2,100,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total								$ 3,300,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Fair Value			$ 1,300,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)	240,428	6,415	115,634	109,140	29,604	94,247		349,568	152,665
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)								1 year
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)								$ 22.66	$ 32.50
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Aggregate Fair Value								$ 6,700,000	$ 1,800,000	1,200,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested								$ 5,000,000	$ 10,200,000
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Awards	200%
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)	218,280		231,268					218,280	231,268
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance	63%	68%	68%	78%	69%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0%	0%	0%	0%	0%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	1.50%	0.20%	0.10%	0.30%	2.50%
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	2 years	2 years	2 years	2 years	2 years
Market-based Restricted Stock [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Awards	200%	200%	200%	200%	200%
Market-based Restricted Stock [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Awards	0%	0%	0%	0%
Market-based Restricted Stock [Member] \| Executive Officer [Member]
Share-Based Payment Arrangement, Expense	$ 6,700,000								$ 0
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)			30,616
Market-based Restricted Stock First Issuance [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Fair Value					$ 3,100,000
Market-based Restricted Stock Second Issuance [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Fair Value				$ 1,200,000
The 2013 Performance Incentive Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)													8,500,000	6,500,000	5,000,000	4,100,000	3,100,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)								456,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares)								2,200,000
Management Performance Bonus Plan 2017 [Member] \| Performance Shares [Member]
Share-Based Payment Arrangement, Expense								$ 0	0	0
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value								$ 0	$ 27,400,000	$ 1,300,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)								0	0	0
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)												1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price (in dollars per share)												$ 1.64
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares (in shares)											999,997	999,997

Note 15 - Share-based Compensat

Note 15 - Share-based Compensation - Stock Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Outstanding, weighted average exercise price (in dollars per share)	$ 2.16
Share-Based Payment Arrangement, Option [Member]
Outstanding (in shares)	624,531	844,455
Outstanding, weighted average exercise price (in dollars per share)	$ 2.13	$ 2
Exercised (in shares)	(161,646)	(183,064)
Exercised, weighted average exercise price (in dollars per share)	$ 2	$ 1.61
Forfeited (in shares)	0	(1,146)
Forfeited, weighted average exercise price (in dollars per share)	$ 0	$ 5.69
Expired (in shares)	(6,592)	(35,714)
Expired, weighted average exercise price (in dollars per share)	$ 3.22	$ 1.73
Outstanding at end of year (in shares)	456,293	624,531
Outstanding, weighted average exercise price (in dollars per share)	$ 2.17	$ 2.13
Stock options exercisable at year end (in shares)	456,293	624,531
Options exercisable, weighted average exercise price (in dollars per share)	$ 2.17	$ 2.13
Performance Shares [Member]
Outstanding (in shares)	0	686,001
Outstanding, weighted average exercise price (in dollars per share)	$ 1.64	$ 1.64
Exercised (in shares)		(686,001)
Exercised, weighted average exercise price (in dollars per share)		$ 1.64
Outstanding at end of year (in shares)		0
Outstanding, weighted average exercise price (in dollars per share)		$ 1.64
Stock options exercisable at year end (in shares)		0
Options exercisable, weighted average exercise price (in dollars per share)		$ 0

Note 15 - Stock-based Compens_4

Note 15 - Stock-based Compensation - Shares Authorized Under Stock Option Plan (Details)	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Number of shares outstanding (in shares) \| shares	456,293
Weighted average remaining contractual life (Year)	2 years 10 months 2 days
Weighted average exercise price (in dollars per share)	$ 2.16
Price Range 1 [Member]
Exercise price, lower range (in dollars per share)	1
Exercise price, upper range (in dollars per share)	$ 1.50
Number of shares outstanding (in shares) \| shares	2,000
Weighted average remaining contractual life (Year)	3 years 10 months 6 days
Weighted average exercise price (in dollars per share)	$ 1.49
Price Range 2 [Member]
Exercise price, lower range (in dollars per share)	1.51
Exercise price, upper range (in dollars per share)	$ 2
Number of shares outstanding (in shares) \| shares	177,500
Weighted average remaining contractual life (Year)	3 years 3 months 10 days
Weighted average exercise price (in dollars per share)	$ 1.90
Price Range 3 [Member]
Exercise price, lower range (in dollars per share)	2.01
Exercise price, upper range (in dollars per share)	$ 2.50
Number of shares outstanding (in shares) \| shares	255,938
Weighted average remaining contractual life (Year)	2 years 4 months 6 days
Weighted average exercise price (in dollars per share)	$ 2.06
Price Range 4 [Member]
Exercise price, lower range (in dollars per share)	2.51
Exercise price, upper range (in dollars per share)	$ 8.60
Number of shares outstanding (in shares) \| shares	20,855
Weighted average remaining contractual life (Year)	4 years 11 months 1 day
Weighted average exercise price (in dollars per share)	$ 5.69

Note 15 - Share-based Compens_2

Note 15 - Share-based Compensation - Restricted Stock Activity (Details) - $ / shares							12 Months Ended
	Feb. 24, 2022	May 03, 2021	Feb. 08, 2021	Mar. 25, 2020	Apr. 01, 2019	Feb. 25, 2019	Dec. 31, 2022	Dec. 31, 2021
Restricted Stock [Member]
Outstanding (in shares)							1,212,783	930,854
Outstanding at beginning of year, grant date fair value (in dollars per share)							$ 37.48	$ 19.31
Granted (in shares)							1,373,909	801,484
Granted, grant date fair value (in dollars per share)							$ 25.26	$ 47.20
Vested (in shares)							(569,535)	(378,502)
Vested, grant date fair value (in dollars per share)							$ 35.51	$ 19.31
Forfeited (in shares)							(137,942)	(141,053)
Forfeited, grant date fair value (in dollars per share)							$ 40.19	$ 36.95
Outstanding (in shares)							1,879,215	1,212,783
Outstanding at end of year, grant date fair value (in dollars per share)							$ 28.94	$ 37.48
Market-based Restricted Stock [Member]
Outstanding (in shares)							139,756	224,774
Outstanding at beginning of year, grant date fair value (in dollars per share)							$ 19.86	$ 19.20
Granted, grant date fair value (in dollars per share)							$ 22.66	$ 32.50
Vested (in shares)	(218,280)		(231,268)				(218,280)	(231,268)
Vested, grant date fair value (in dollars per share)							$ 10.95	$ 26.98
Forfeited (in shares)							0	(6,415)
Forfeited, grant date fair value (in dollars per share)							$ 0	$ 40.65
Outstanding (in shares)							271,044	139,756
Outstanding at end of year, grant date fair value (in dollars per share)							$ 30.64	$ 19.86
Granted (in shares)	240,428	6,415	115,634	109,140	29,604	94,247	349,568	152,665

Note 15 - Share-based Compens_3

Note 15 - Share-based Compensation - Stock Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Stock compensation expense	$ 25,334	$ 13,956	$ 5,981
Research and Development Expense [Member]
Stock compensation expense	3,176	1,906	1,012
Selling and Marketing Expense [Member]
Stock compensation expense	3,649	1,788	852
General and Administrative Expense [Member]
Stock compensation expense	14,066	8,061	3,518
Cost of Sales [Member]
Stock compensation expense	$ 4,443	$ 2,201	$ 599

Note 16 - Income Taxes (Details

Note 16 - Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Sep. 01, 2021	May 03, 2021	Oct. 01, 2020
Stock-based Compensation, Tax Benefits	$ 0	$ 10,500	$ 3,200
Deferred Tax Liabilities, Intangible Assets	6,150	35,241
Operating Loss Carryforwards	128,600
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	39,500
Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration	89,100
Deferred Tax Assets, Capitalized Research and Development	$ 2,405	0
GCI Acquisition [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities		24,100			$ 24,133
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount		8,000
Sexton Acquisition [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities		$ 1,500		$ 1,482
SciSafe Holdings, Inc [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities						$ 3,297
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount			3,300
Deferred Tax Liabilities, Intangible Assets			$ 3,300

Note 16 - Income Taxes - Schedu

Note 16 - Income Taxes - Schedule of Income before Income Tax, Domestic and Foreign (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Domestic	$ (146,091)	$ (28,590)	$ (1,281)
Foreign	1,264	(436)	0
Total	$ (144,827)	$ (29,026)	$ (1,281)

Note 16 - Income Taxes - Provis

Note 16 - Income Taxes - Provision (Benefit) for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Federal	$ 0	$ 0	$ 0
State	11	0	33
Foreign	205	9	0
Total current tax provision	216	9	33
Federal	(2,924)	(17,703)	(3,297)
State	(2,314)	(2,424)	0
Foreign	0	0	0
Total deferred tax benefit	(5,238)	(20,127)	(3,297)
Income tax benefit	$ (5,022)	$ (20,118)	$ (3,264)

Note 16 - Income Taxes - Effect

Note 16 - Income Taxes - Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Federal statutory tax	21%	21%	21%
State tax, net of federal benefit	3%	7%	20%
Stock compensation	0%	36%	251%
Sec. 162(m) limitation on executive compensation	(1.00%)	(11.00%)	(16.00%)
Fair value change in contingent consideration	1%	(2.00%)	(38.00%)
Fair value change in warrant liability	0%	0%	59%
Transaction costs	0%	(1.00%)	(3.00%)
Gain on stock acquisition	0%	5%	0%
Tax credits	1%	0%	6%
Change in valuation allowance	(21.00%)	20%	4%
Expired net operating losses	0%	(5.00%)	(47.00%)
Other	0%	(1.00%)	(2.00%)
Total	4%	69%	255%

Note 16 - Income Taxes - Deferr

Note 16 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Net operating loss carryforwards	$ 29,102	$ 27,500
Stock-based compensation	3,207	2,066
Accruals and reserves	3,724	3,402
Inventory	425	236
Lease liabilities	3,653	4,198
Tax credit carryforward	1,423	594
Capitalized research and development	2,405	0
Other	445	318
Total deferred tax assets	44,384	38,314
Intangibles	(6,150)	(35,241)
Right-of-use assets	(3,458)	(4,070)
Fair value change in investments	(447)	(294)
Fixed assets	(1,177)	(1,203)
Other	0	0
Total deferred tax liabilities	(11,232)	(40,808)
Net deferred tax (liabilities) assets before valuation allowance	33,152	(2,494)
Less: valuation allowance	(33,402)	(2,993)	$ (8,498)	$ (8,706)
Net deferred tax liabilities	$ (250)	$ (5,487)

Note 16 - Income Taxes - Change

Note 16 - Income Taxes - Change in Valuation Allowance for Deferred Tax Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Balance	$ 2,993	$ 8,498	$ 8,706
Deferred tax liabilities assumed through acquisitions	0	(8,498)	(3,297)
Charged to income tax expense	30,409	2,993	3,089
Balance	$ 33,402	$ 2,993	$ 8,498

Note 16 - Income Taxes - Summar

Note 16 - Income Taxes - Summary of Income Tax Contingencies (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Balance	$ 255	$ 96
Increase related to prior year tax positions	170	0
Increase related to current year tax positions	185	159
Balance	$ 610	$ 255

Note 17 - Acquisitions (Details

Note 17 - Acquisitions (Details Textual) - USD ($)					3 Months Ended		8 Months Ended	12 Months Ended
Note 17 - Acquisitions (Details Textual) - USD ($)	Sep. 01, 2021	May 03, 2021	Oct. 01, 2020	Sep. 30, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain (Loss), Net, Total								$ 0	$ 6,451,000	$ 0
Goodwill, Ending Balance					$ 224,741,000	$ 58,449,000	$ 224,741,000	$ 224,741,000	$ 224,741,000	$ 58,449,000
Sexton Acquisition [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)	530,502
Business Acquisition, Percentage of Equity Issuable Shares Held in Escrow Accounts for Post Closing Claims	10%
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain (Loss), Net, Total	$ 6,500,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Gross Receivables	509,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Uncollectable Receivables	17,000
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments Related to Previous Period					198,000
Goodwill, Ending Balance	$ 28,470,000
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual					1,800,000
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual					(1,000,000)
Sexton Acquisition [Member] \| Common Stock Issued to Acquire Participating Holders [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)	477,452
Sexton Acquisition [Member] \| Common Stock Deposited Into Escrow [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)	53,050
GCI Acquisition [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)		6,636,470
Business Acquisition, Percentage of Equity Issuable Shares Held in Escrow Accounts for Post Closing Claims		9%
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Gross Receivables		$ 7,100,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Uncollectable Receivables		53,000
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments Related to Previous Period					$ 607,000
Goodwill, Ending Balance		$ 137,822,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares, Before Adjustments (in shares)		6,646,870
Business Combination, Stock Reduced During Period, Satisfy Note Receivable (in shares)		10,400
Business Combination, Escrow Shares, Period (Month)		24 months
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual							39,100,000
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual							$ (19,600,000)
GCI Acquisition [Member] \| One GCI Stockholder [Member]
Business Combination, Stock Reduced During Period, Satisfy Note Receivable (in shares)		10,400
Financing Receivable, after Allowance for Credit Loss, Total		$ 374,000
SciSafe Holdings, Inc [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)			611,683
Goodwill, Ending Balance			$ 24,943,000
Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage			100%
Business Acquisition, Share Price (in dollars per share)			$ 29.29
Payments to Acquire Businesses, Gross			$ 15,000,000
Business Acquisition, Amount Held in Escrow			1,500,000
Payments to Acquire Notes Receivable				$ 500,000
Business Combination, Indemnification Assets, Amount as of Acquisition Date			$ 130,000
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual						1,800,000
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual						$ (416,000)
SciSafe Holdings, Inc [Member] \| Maximum [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)			626,000

Note 17 - Acquisitions - Consid

Note 17 - Acquisitions - Consideration (Details) - USD ($) $ / shares in Units, $ in Thousands	Sep. 01, 2021	May 03, 2021	Oct. 01, 2020	Mar. 19, 2021
BioLife stock price (in dollars per share)	$ 60.50	$ 35.07
BioLife shares outstanding (as of March 19, 2021) (in shares)				33,401,359
Sexton Acquisition [Member]
Merger consideration shares (in shares)	530,502
Value of issued shares	$ 32,095
plus: Fair value of BioLife’s existing investment in Sexton	7,951
less: Net working capital adjustment	(118)
Merger Consideration	39,928
Working capital adjustment	$ 118
SciSafe Holdings, Inc [Member]
Merger consideration shares (in shares)			611,683
Value of issued shares			$ 17,916
less: Net working capital adjustment			53
Merger Consideration			36,526
Cash consideration			15,000
Contingent consideration			3,663
Working capital adjustment			$ (53)
GCI Acquisition [Member]
Merger consideration shares (in shares)		6,636,470
Value of issued shares		$ 232,741
Merger Consideration		$ 234,909
Merger consideration percentage		19.90%
Merger consideration shares (in shares)		6,646,870
less: Merger consideration shares withheld to satisfy outstanding GCI stockholder obligations to GCI (in shares)		10,400
plus: Settlement of BioLife prepaid deposits		$ 2,152
plus: Net settlement of BioLife accounts receivable		$ 16

Note 17 - Acquisitions - Fair V

Note 17 - Acquisitions - Fair Value of Net Assets Acquired (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Sep. 01, 2021	May 03, 2021	Dec. 31, 2020	Oct. 01, 2020
Goodwill	$ 224,741	$ 224,741			$ 58,449
Sexton Acquisition [Member]
Cash			$ 1,516
Accounts receivable, net			492
Inventory			1,310
Prepaid expenses and other current assets			670
Property, plant and equipment, net			737
Operating lease right-of-use assets, net			470
Goodwill			28,470
Accounts payable			(291)
Lease liabilities, operating			(470)
Deferred tax liability		(1,500)	(1,482)
Other liabilities			(316)
Fair value of net assets acquired			39,928
Sexton Acquisition [Member] \| Customer Relationships [Member]
Developed technology			2,276
Sexton Acquisition [Member] \| Trade Names [Member]
Developed technology			2,324
Sexton Acquisition [Member] \| Developed Technology Rights [Member]
Developed technology			4,132
Sexton Acquisition [Member] \| Noncompete Agreements [Member]
Developed technology			$ 90
GCI Acquisition [Member]
Cash				$ 43
Accounts receivable, net				7,076
Inventory				15,547
Prepaid expenses and other current assets				639
Property, plant and equipment, net				3,512
Operating lease right-of-use assets, net				1,741
Goodwill				137,822
Accounts payable				(9,837)
Lease liabilities, operating				(1,880)
Deferred tax liability		$ (24,100)		(24,133)
Other liabilities				(7,464)
Fair value of net assets acquired				234,909
Financing lease right-of-use assets, net				114
Long-term deposits and other assets				4
Line of credit				(4,231)
Lease liabilities, financing				(114)
Long-term debt				(4,410)
GCI Acquisition [Member] \| Indefinite In Process Research and Development [Member]
In-process research and development				67,440
GCI Acquisition [Member] \| Customer Relationships [Member]
Developed technology				7,020
GCI Acquisition [Member] \| Trade Names [Member]
Developed technology				26,640
GCI Acquisition [Member] \| Developed Technology Rights [Member]
Developed technology				18,140
GCI Acquisition [Member] \| Noncompete Agreements [Member]
Developed technology				$ 1,240
SciSafe Holdings, Inc [Member]
Cash						$ 500
Accounts receivable, net						945
Prepaid expenses and other current assets						31
Property, plant and equipment, net						3,400
Developed technology						12,100
Goodwill						24,943
Accounts payable						(885)
Deferred tax liability						(3,297)
Other liabilities						(2,758)
Fair value of net assets acquired						36,526
Other assets						1,547
SciSafe Holdings, Inc [Member] \| Customer Relationships [Member]
Developed technology						7,420
SciSafe Holdings, Inc [Member] \| Trade Names [Member]
Developed technology						4,020
SciSafe Holdings, Inc [Member] \| Noncompete Agreements [Member]
Developed technology						$ 660

Note 17 - Acquisitions - Acquir

Note 17 - Acquisitions - Acquired Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 01, 2021	May 03, 2021	Oct. 01, 2020
Total identifiable intangible assets	$ 8,822
Sexton Acquisition [Member] \| Developed Technology Rights [Member]
Developed technology	$ 4,132
Sexton Acquisition [Member] \| Developed Technology Rights [Member] \| Minimum [Member]
Intangible assets, estimated useful life (Year)	5 years
Sexton Acquisition [Member] \| Developed Technology Rights [Member] \| Maximum [Member]
Intangible assets, estimated useful life (Year)	9 years
Sexton Acquisition [Member] \| Customer Relationships [Member]
Developed technology	$ 2,276
Intangible assets, estimated useful life (Year)	2 years
Sexton Acquisition [Member] \| Trade Names [Member]
Developed technology	$ 2,324
Intangible assets, estimated useful life (Year)	11 years
Sexton Acquisition [Member] \| Noncompete Agreements [Member]
Developed technology	$ 90
Intangible assets, estimated useful life (Year)	1 year
GCI Acquisition [Member]
Total identifiable intangible assets		$ 120,480
GCI Acquisition [Member] \| Indefinite In Process Research and Development [Member]
In-process research and development		67,440
GCI Acquisition [Member] \| Developed Technology Rights [Member]
Developed technology		$ 18,140
Intangible assets, estimated useful life (Year)		6 years
GCI Acquisition [Member] \| Customer Relationships [Member]
Developed technology		$ 7,020
Intangible assets, estimated useful life (Year)		12 years
GCI Acquisition [Member] \| Trade Names [Member]
Developed technology		$ 26,640
Intangible assets, estimated useful life (Year)		15 years
GCI Acquisition [Member] \| Noncompete Agreements [Member]
Developed technology		$ 1,240
Intangible assets, estimated useful life (Year)		4 years
SciSafe Holdings, Inc [Member]
Developed technology			$ 12,100
SciSafe Holdings, Inc [Member] \| Customer Relationships [Member]
Developed technology			$ 7,420
Intangible assets, estimated useful life (Year)			14 years
SciSafe Holdings, Inc [Member] \| Trade Names [Member]
Developed technology			$ 4,020
Intangible assets, estimated useful life (Year)			19 years
SciSafe Holdings, Inc [Member] \| Noncompete Agreements [Member]
Developed technology			$ 660
Intangible assets, estimated useful life (Year)			4 years

Note 17 - Acquisitions - Pro Fo

Note 17 - Acquisitions - Pro Forma Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Sexton Acquisition [Member]
Total revenue	$ 122,494	$ 50,856
Net loss	(9,860)	(1,028)
GCI Acquisition [Member]
Total revenue	143,732	87,370
Net loss	$ (16,375)	501
SciSafe Holdings, Inc [Member]
Total revenue		52,613
Net loss		$ 1,798

Note 18 - Employee Benefit Pl_2

Note 18 - Employee Benefit Plan (Details Textual) - Defined Contribution Plan, 401 K [Member] - Pension Plan [Member] - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	100%
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 1,000,000	$ 822,000	$ 347,000